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The ability of uropathogenic Escherichia coli (UPEC) to successfully establish an 
infection within the urinary tract relies on the pathogen to be able to navigate the complex 
interactions between pathogen and host. During a urinary tract infection (UTI), UPEC must 
ascend, adhere, and form bacterial communities in various infection niches, from the bladder 
(cystitis) to the kidneys (pyelonephritis). Each of these steps is critical for bacterial survival, and 
host and pathogen factors required at each stage can vary depending on host sex and anatomic 
niche. Preclinical modeling of pyelonephritis and sex effects on UTI has been limited due to the 
propensity for kidney infections in standard female murine catheterization models to resolve 
spontaneously, and technical barriers to infection of male mice via catheter. As a result, host and 
bacterial factors involved in pyelonephritis and male UTI remain incompletely defined. 
Here, we employed newly developed in vivo and in vitro models to begin addressing this 
gap in our understanding of UTI pathogenesis. In these models, we found that male and 
xii 
androgenized murine hosts with vesicoureteral reflux develop severe pyelonephritis, leading to 
the formation of penetrant renal abscesses. We also demonstrated the presence and localization 
of kidney bacterial communities (KBCs) that nucleate renal abscess formation, and identified 
KBC formation as a key pathogenic stage in pyelonephritis.  
We sought to define UPEC community behavior during abscess formation, as ascension 
into the kidney has been thought to impose a severe population bottleneck. Using a set of 
“barcoded” isogenic UPEC isolates and confocal microscopy, we defined the spatial and 
temporal dynamics of UPEC populations during experimental ascending pyelonephritis in mice. 
Further, we found that KBCs were clonal, and thus ascension into the nephron is a relatively 
uncommon event accomplished by single bacteria within a nephron unit. 
Once UPEC arrives within a nephron, it must adhere in order to withstand the shear force 
of urine flow and to enable replication and ultimately KBC formation. Type 1 pili and the tip 
adhesin FimH have long been recognized to be critical for UPEC adhesion to bladder epithelium. 
However, we demonstrated an essential role for type 1 pili in colonizing the kidney during 
pyelonephritis and showed that mannosides (novel small-molecule inhibitors of FimH) can limit 
the severity of experimental pyelonephritis. Further, by performing a lentiviral CRISPR screen in 
cultured renal collecting duct epithelial cells, we identified desmoglein-2, a mannosylated, 
surface-expressed tight junctional protein, as the first known kidney receptor for FimH. Using 
cellular assays and biochemical approaches, we confirmed that desmoglein-2 binds FimH and 
that this interaction is critical for UPEC binding to collecting duct cells.  
Effective and personalized future treatment of UTIs will rely on a deep mechanistic 
understanding of host-pathogen interactions mediating each step of the virulence cascade, in all 
urinary tract niches and in both host sexes. The present work suggests that androgen modulation 
xiii 
may represent a new therapeutic or preventive strategy for UTI in selected males and in women 
with hyperandrogenic conditions, such as polycystic ovary syndrome. Further, identification of 
the FimH-Dsg2 interaction in the kidney indicates that mannosides and vaccines that target 
FimH binding can be further developed as non-antibiotic approaches to pyelonephritis.  
1 
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Abstract 
The clinical syndromes comprising urinary tract infection (UTI) continue to exert 
significant impact on millions of patients worldwide, most of whom are otherwise healthy 
women. Antibiotic therapy for acute cystitis does not prevent recurrences, which plague up to 
one fourth of women after an initial UTI. Rising antimicrobial resistance among uropathogenic 
bacteria further complicates therapeutic decisions, necessitating new approaches based on 
fundamental biological investigation. Here, we highlight contemporary advances in the field of 





A Pervasive and Persistent Problem 
Urinary tract infections (UTIs) are among the most common bacterial infections, 
affecting 150 million people worldwide each year (1-3). Although both men and women may 
become infected, UTIs are traditionally thought of as a disease of women, among whom 50% 
will be affected across their lifespan (2). Approximately 25% of women presenting with a first 
episode of bacterial cystitis go on to suffer recurrent UTI within 6 months, some having 6 or 
more infections in the year following the initial episode (2, 4). Current therapeutics are 
suboptimal, as the prevalence of multidrug-resistant uropathogens is increasing and antibiotic 
treatment for acute infection does not preclude recurrences (2, 5, 6). These recalcitrant infections 
can become a significant health problem and diminish quality of life for affected men and 
women.  
Bacterial infections of the urinary tract (UT) present clinically with a variety of signs and 
symptoms and may be caused by an array of organisms (see Figure 1). Here, we focus primarily 
on uropathogenic Escherichia coli (UPEC) as the etiologic agent of UTI, as UPEC is responsible 
for >80% of all community-acquired infections (2). Other etiologies include Staphylococcus, 
Klebsiella, Enterobacter, Proteus, and Enterococcus; these organisms become particularly 
relevant during catheter-associated and healthcare-associated infections (7, 8). The pathogenic 
cascade of UPEC cystitis has been extensively studied in recent years, largely in cell-culture and 
mouse models, as mice recapitulate many facets of the bladder epithelial environment (reviewed 
in (9)). Through these studies, unprecedented light has been shed on the molecular and cellular 
basis of infection. Further, recent years have seen the advent of several new mouse models, 
enabling the study of complicated UTIs (pyelonephritis, renal abscess, catheter-associated UTI) 
and recurrent cystitis. In addition, recent data suggest that the normal, healthy bladder is not 
3 
always sterile, and a picture of the urinary microbiome is emerging. Such advances promise to 
further illuminate molecular mechanisms of virulence in UPEC (reviewed in (10)) and other 
uropathogens, as well as the intricacies of the host immune response. With these approaches, we 
are poised to address heretofore unanswered questions with clinical relevance to UTI treatment 
and prevention.  
 
Molecular Pathogenesis of UTI 
Infection of the urinary tract begins when UPEC, likely introduced after colonization of 
the periurethral area by gastrointestinal tract flora (11-13), accesses and ascends the urethra by 
incompletely defined mechanisms. Upon reaching the urinary bladder, UPEC bind to superficial 
epithelial (facet) cells in a type 1 pili-dependent manner (14) (see UPEC Virulence Factors: 
Adhesins). A subset of adherent bacteria are then internalized into facet cells (15, 16), a dynamic 
process that likely relies on the normal cycling of apical membrane segments in these cells (17). 
Countering this key pathogenic activity, bladder epithelial cells undertake active expulsion of 
internalized UPEC. Recent data show that UPEC are capable of neutralizing the lysosome, and 
that this neutralization is sensed by a lysosomal membrane protein called mucolipin TRP channel 
3 (TRPML3), activating pathways that direct exocytosis of UPEC-containing lysosomes (18). 
Through a distinct mechanism, activation of Toll-like receptor 4 (TLR4) by internalized UPEC 
leads to specific ubiquitination of TRAF3, enabling its interaction with a guanine-nucleotide 
exchange factor that directs assembly of the exocyst complex, thereby also accomplishing 
expulsion of intracellular bacteria (19). 
Using strategies that are poorly understood, UPEC can gain access to the bladder 
epithelial cell cytoplasm, thereafter developing clonal, biofilm-like masses termed intracellular 
4 
bacterial communities (IBCs) (15, 20). As part of the host response, most superficial epithelial 
(facet) cells are exfoliated (21), liberating IBCs into the urine and ridding the body of thousands 
of bacteria. Shed IBC-bearing cells are observed in the urine of infected women and children, 
supporting their clinical relevance (22, 23). After 16-24 h in murine UTI models, a subset of 
UPEC in remaining IBCs adopt a neutrophil-resistant, filamentous morphology and escape the 
IBCs, subsequently re-invading naïve bladder epithelial cells (24). Some of these bacteria will go 
on to infect immature bladder epithelium which is exposed after exfoliation, later forming 
quiescent intracellular reservoirs, which avoid immune clearance and resist systemic antibiotic 
treatment (25-27). These persistent UPEC may re-emerge, in response to currently undefined 
signals, to cause the recurrent cystitis that is so common clinically.  
A significant gap in our understanding is the mechanism by which UPEC escape the 
initial vacuole (after internalization) to reach the cytoplasm, where the IBC is formed. Unlike 
other Gram-negative pathogens that escape an endosome, UPEC do not encode a type III 
secretion system to deliver virulence factors (28). Further, the bottleneck imposed by IBC 
formation in the bladder precludes classical in vivo mutant screens, and no in vitro model for 
IBC formation has been wholly accepted by the field (14, 15). As a result, surrogate methods 
have been used to illuminate requirements for IBC formation. For example, since IBCs exhibit 
many characteristics of biofilms, one group performed a transposon screen for genes necessary 
for in vitro biofilm formation, using polyvinyl chloride as substrate as well as sampling the 
pellicle of standing broth cultures. This screen yielded genes with functions in attachment, 
motility, LPS synthesis and modification, metabolism, as well as bacterial cell maintenance (29). 
In other studies, murine UTI models have shown that single-gene mutants of UPEC exhibit 
defects in specific steps of the IBC pathogenic cascade, as in the case of OmpA, a major outer 
5 
membrane porin. OmpA deletion does not inhibit UPEC binding to superficial epithelial cells or 
internalization; however, once within the cytoplasm of these cells, UPEC ΔompA cannot 
complete the intracellular pathway and, as assessed by dwindling organ bacterial loads and 
confocal microscopy, fails to progress past very early stages of IBC formation in mice (30). 
Similarly, UPEC harboring a deletion of the small non-coding RNA Hfq cannot replicate within 
cultured human bladder epithelial cells, despite exhibiting normal levels of binding and invasion 
(31). Defining the roles of relevant host factors (exemplified by the exocytosis studies mentioned 
above) will also help to elucidate the mechanism by which UPEC accesses the critical 
cytoplasmic niche. Answering these questions will require collaborative and broad-based efforts 
involving cell biology, bacterial physiology, biochemistry, and optimized in vitro or ex vivo 
models. 
Following escape into the cytoplasm, the bacteria find themselves occupying an 
environment very different from the nutrient-poor bladder lumen. Transcriptomic analyses of 
UPEC in different models (such as during murine UTI or bacterial growth in urine) have 
suggested that various metabolic pathways are essential for pathogenesis; these include sialic 
acid transport/metabolism, gluconeogenesis, the tricarboxylic acid (TCA) cycle, iron uptake, 
ethanolamine and phosphate metabolism, as well as amino acid metabolism (32-35) (reviewed in 
(36)). Although this work has provided broad insight into the metabolic activities required to 
cause UTI, we are on the verge of being able to specifically interrogate UPEC populations in 
defined niches and times during infection. UPEC survival and growth at distinct spatiotemporal 
points during infection could rely on very different metabolic sources. Intracellular survival 
presumably requires a unique set of metabolic capabilities, but the precise needs are 
incompletely defined. Metabolism of a chromogenic substrate during cystitis provides 
6 
circumstantial evidence that UPEC can utilize β-galactosidase, perhaps reflecting a glucose-
limited milieu during this intracellular step (37). Transcriptional profiling from whole mouse 
bladders 6 h post infection with UPEC strain UTI89 was posited to reflect mostly bacteria that 
are internalized and actively forming IBCs (38). This analysis found that 2.3% of the UPEC 
genome was differentially regulated within the bladder at this time point (6 h), when compared to 
the statically grown UPEC broth culture that was used as inoculum. Genes associated with 
alternative carbon source utilization pathways, such as lacZ and srlA for galactose and sorbitol 
utilization, respectively, were upregulated; deletion of lacZ was subsequently found to impair 
virulence (38). Genes associated with iron acquisition were also highly expressed, including 
siderophores (secreted bacterial proteins that chelate extracellular iron and return it to the 
bacterial cell). In contrast, tryptophan and cysteine synthetic genes were downregulated, 
reflecting an abundance of these amino acids within the IBC niche (38). A more specific 
understanding of bacterial metabolism within pathogenic niches could reveal points of potential 
intervention, to halt infection and/or eliminate reservoirs that seed recurrent UTIs. Of note, the 
central metabolic pathways in E. coli do not necessarily represent all uropathogenic species; 
other pathogens with distinct metabolism may respond to different nutritional cues during 
infection (32).  
Comparatively less is known about the molecular pathogenesis of infection in the kidney. 
In traditional animal models (female mice of most strains), severe kidney infection (including 
renal abscess formation) is quite uncommon, hampering the study of this entity. Attenuation in 
mouse models of kidney infection has been observed with UPEC mutants lacking specific 
virulence factors, such as type 1 pili, P pili, flagella, α-hemolysin, and cytotoxic necrotizing 
factor 1 (CNF1) (3, 10). Further, host genetics appear to play a role in susceptibility to acute 
7 
pyelonephritis. For example, data suggest that innate immune defenses play a critical role in 
control of urinary pathogens (39). Increased risk of acute pyelonephritis and renal scarring have 
been linked to polymorphisms reducing expression of IRF3 (encoding a pro-inflammatory 
transcription factor) or CXCR1 (encoding IL-8 receptor) in certain UTI-prone patient populations 
(39-41). Compared to the understanding of bacterial cystitis, the understanding of pyelonephritis 
remains limited and, consequently, a fertile area of study. 
 
UPEC Virulence Factors: Adhesins 
UPEC contains a mosaic of virulence factors that work in concordance with host 
background in order to establish infection. An extensive review of UPEC virulence factors has 
been done elsewhere (3). Here, however, we discuss chaperone-usher pathway (CUP) pili, major 
adhesive structures used by UPEC to establish tropisms within various environmental and host 
niche. CUP pili are part of a broadly conserved molecular paradigm for Gram-negative bacterial 
secretion of heteropolymeric surface structures. Expression of pili on the surface of bacteria 
involves delivery of structural subunits by the periplasmic chaperone to the outer membrane 
usher for assembly through the outer membrane. On the bacterial surface, the pilus structure 
includes the tip adhesin, adapters, and repeating subunits of the helical pilus rod. Each subunit 
has its immunoglobulin-like fold completed by a strand provided by the next subunit, reflecting a 
process called donor-strand complementation (DSC) (42). The energetic favorability provided by 
this final structure drives assembly on the periplasmic side of the usher, as the periplasm is 
devoid of ATP (43). The adhesin subunit is located at the binding tip of the pilus and is 
comprised of a pilin domain and a lectin domain. The lectin domain binds sugars with 
stereochemical specificity, providing the tropism that characterizes each CUP pilus (reviewed in 
8 
(44-46)). A given UPEC strain can encode up to 16 CUP operons; for many of these, a specific 
function has yet to be elucidated. Specifically, the genome of UPEC strain UTI89 contains 
approximately 10 CUP pili operons (8-9 complete operons and 2 incomplete operons; Figure 2) 
(47, 48). Here, we discuss two of the best studied and most relevant CUP pili to UTI 
pathogenesis: type 1 pili and P pili. 
 
Type 1 pili  
Type 1 pili (encoded by the fim operon) have long been considered the major 
urovirulence factor during cystitis. One of the first pathogenic steps of cystitis is binding of the 
UPEC type 1 pilus adhesin (FimH) to α-D-mannosylated uroplakins on the apical (luminal) 
surfaces of superficial epithelial (facet) cells of the bladder (49-51). This binding event allows to 
bacteria to avoid elimination during urine voiding and activates a signaling cascade that leads to 
UPEC internalization into the facet cells, where IBCs are subsequently formed in the facet cell 
cytoplasm. Within the IBCs, type 1 pili then participate in interbacterial interactions, forming 
biofilm-like communities (20, 21, 52, 53). 
Recent work has identified structural variants that help to illuminate the function of type 
1 pili as a molecular tether in the bladder. The tip adhesin FimH can transition between tensed 
and relaxed conformational states (with low and high binding affinity to mannose, respectively) 
to modulate UPEC binding. A balance between these states allows optimal epithelial binding by 
UPEC within the bladder environment (52, 54). The variant adhesin FimHA27V/V163A displays 
higher in vitro affinity for mannose than wild-type FimH, but UPEC expressing this variant are 
attenuated during murine cystitis. This could reflect that higher-affinity binding to mannose 
causes less frequent interactions with the bladder epithelium (catch-bond mechanism) or that the 
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variant more effectively binds decoy receptors such as Tamm-Horsfall glycoprotein (48, 54, 55). 
Regardless of mechanism, the attenuation of this variant in the bladder demonstrates the 
functional importance of these FimH conformational states.  
The importance of type 1 pili during bladder infection is highlighted through both mouse 
models and human studies. Lack of the pilus and adhesin causes near-complete abrogation of 
acute cystitis in mice (16, 20, 21, 53). In humans, UPEC attached to shed urothelial cells express 
type 1 pili, while expression is relatively lacking in bacteria recovered unbound in urine (56-59). 
Given the importance of the FimH-mannose interaction, novel therapeutics are being developed 
to target bacterial attachment (see Next-generation Therapeutics). 
 
P pili 
P pili have been considered the major adhesin during pyelonephritis. P pili (encoded by 
the pap operon) bind α-D-galactopyranosyl-(1,4)-β-D-galactopyranoside and appear to contribute 
to pyelonephritis in some species (60, 61). P pili are enriched in the genomes of UPEC isolates 
from children with acute pyelonephritis (62, 63). Allelic variation in the P pilus adhesin PapG 
correlates with differing affinity for various glycolipid receptors that are differentially expressed 
in the kidneys of humans and model animals, including mice (44, 64). Specifically, the mouse 
does not significantly express the human PapGII receptor, the globoside Gb04 (64). As noted 
above, female mice of most strains are generally resistant to severe kidney infection, or it is self-
limited (see Emerging, Clinically Relevant Models for UTI); therefore, understanding the role 




Immune Control and Pathogen Evasion 
After ascending the urethra, bacterial pathogens are challenged by innate defenses within 
the bladder. Arrival in the bladder triggers a TLR4-dependent, lipopolysaccharide (LPS)-
stimulated inflammatory response from bladder epithelial cells and resident leukocytes, 
culminating in activation of the NF-κB pathway, which promotes expression of inflammatory 
cytokines and neutrophil chemoattractants (65). This inflammatory milieu engenders massive 
neutrophil influx into the bladder tissue and lumen, reflecting a diagnostic hallmark of UTI. The 
importance of this neutrophil influx in controlling UPEC infection has been well established 
(e.g., (66-69)). Production of polysaccharide capsule by UPEC, particularly of the K2 or K1 
serotype, may provide some protection against complement-mediated killing (70). Further, many 
other soluble factors (e.g., antimicrobial peptides, complement, lipocalin-2, lysozyme, 
lactoferrin) are also released by host cells into the urinary space, potentially creating a less 
hospitable environment for arriving bacteria (71, 72). Antimicrobial peptides likely protecting 
the urinary tract include defensins, the human cathelicidin LL-37, and ribonuclease 7 (73-76). 
These molecules may exert direct antimicrobial activity, augment innate cellular recruitment, or 
function to alter the environmental niche to make it less favorable for uropathogens (e.g., by 
sequestering siderophores and the critical nutrient iron from the bacteria) (77). One such host 
factor, lipocalin-2 (neutrophil gelatinase-associated lipocalin (NGAL)), is secreted into the urine 
during UTI and acts as a predictive biomarker for UTI in febrile infants, young children, and 
women with recurrent UTI, as well as limiting bacterial clearance in mouse models (77-79). Host 
transcriptional regulators such as hypoxia-inducible factor 1α are also expressed in response to 
bacteria, potentially boosting innate defense components such as nitric oxide, cathelicidin, and β-
defensin 2 (77, 80). The humoral pattern recognition molecule pentraxin 3 (PTX3) has been 
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shown to help control UTI by serving as an opsonin and promoting bacterial uptake by 
neutrophils; UTI-prone children and adult cystitis patients who had suffered recurrent UTI as 
children exhibited polymorphisms in PTX3 (81), suggesting that the cellular and soluble 
components of innate immunity can influence disease outcomes. As uropathogens ascend into 
the kidneys, the bacteria encounter additional innate defenses. In addition to IRF3 and CXCR1 
(see Molecular Pathogenesis of UTI), the roles of the cytokines IL-6 and IL-8 during ascending 
pyelonephritis has been a major focus of study (39). IL-6 stimulates antimicrobial peptide 
expression and monocyte proliferation (82-84). In children with pyelonephritis, high IL-6 serum 
and urine concentrations correlated with the presence of renal scarring (85, 86). As discussed 
above, IL-8 expression facilitates neutrophil transmigration to infected areas and polymorphisms 
reducing expression of its receptors (CXCR1 and CXCR2) are linked to a risk of acute 
pyelonephritis (41, 87). Thus, an effective, controlled innate response is critical for effective 
clearance of uropathogens (39, 88).  
Formation of IBCs is a key means by which bacteria subvert neutrophil activity, as 
arriving neutrophils accurately locate IBC-bearing facet cells but cannot access the bacteria 
within (65, 89). UPEC can subvert and delay the innate immune response, and thus the arrival of 
neutrophils, in multiple ways (reviewed in (65)). For example, liberation of the effector YbcL by 
UPEC leads to a measurable dampening of neutrophil infiltration into the bladder (90-92). 
Further, UPEC induces host expression of genes such as IDO, which, via generation of 
kynurenine metabolites, can attenuate neutrophil migration across infected bladder epithelia, 
both in a Transwell system and in mice (93, 94). Some UPEC strains, such as CFT073, can also 
disrupt host signaling by producing TIR domain-containing proteins such as TcpC; this virulence 
factor interacts with host adaptor MyD88 to disrupt TLR4 signaling, also reducing urinary IL-1β 
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in mice and inhibiting the NLRP3 inflammasome in macrophages (95, 96). While robust innate 
defenses are able to repel most bacterial challenges, this inflammatory response may represent a 
double-edged sword. In murine cystitis, excessive inflammation and resulting bladder tissue 
damage predisposes the host to worse infection outcomes, including chronic cystitis (88, 97, 98).  
As mucosal barriers such as the bladder epithelium are repeatedly assaulted with bacteria, 
they are generally tolerant to transient microbial presence, and innate defenses are key to prevent 
infection. However, clinical syndromes such as recurrent UTI raise questions about the 
importance of adaptive immunity in bladder protection. Pro-inflammatory cytokines that also 
elicit adaptive immune effects, such as IL-17, are prominently secreted during the acute phase of 
murine experimental UTI (99, 100). CD8+ T cells are recruited to the bladder as early as 24 h 
post infection, but the precise roles of these and other adaptive immune cell populations are 
unknown (101). Regarding humoral immunity, the prevalence of recurrent UTI in the female 
population suggests that a lasting protective immune response is not established following 
cystitis, at least in this subpopulation of women (102). Upper-tract UTI (pyelonephritis) may 
elicit a more robust serological response, although it is not clear if antibodies generated against 
UPEC antigens here would subsequently reach the bladder to provide protection against future 
cystitis. In total, the mechanisms by which adaptive immunity might help to control UPEC 
infection are substantially understudied in comparison with the innate immune system. 
Understanding the basis of functional adaptive immunity against UTI could have major 





The Present and Future of UTI Diagnostics 
For decades, the diagnosis of UTI has relied on culturing urine samples and looking 
under the microscope for white blood cells. Providers also utilize point-of-care dipstick tests to 
assay the presence of leukocyte esterase, nitrites, and other compounds. Even in combination 
with careful symptom history and risk factor ascertainment, these tests offer only 50-85% 
sensitivity and 80-90% specificity (103). Further, community diagnosis of UTI is typically made 
on clean-catch urine samples, raising the possibility of contamination and rendering some 
positive cultures difficult to interpret (including “false-positives”). In the age of “omics,” 
widespread mass spectroscopy, point-of-care molecular detection, bacterial genomic sequencing, 
and other tools, the time is right to move toward better UTI diagnostics. These might rely on a 
combination of host immune and metabolic markers, as well as on the detection of uropathogens 
and their components (DNA, proteins, etc.). For example, if sample preparation challenges could 
be circumvented, direct mass spectrometry on infected urine might be useful, detecting bacteria 
promptly in urine without the need to wait for growth on solid media (104). Alternatively, rapid 
molecular identification of E. coli at the substrain level, as well as prediction of antibiotic 
resistances, might enable more efficient selection of antibiotics for treatment (105, 106). 
Ultimately, improved and accurate diagnostics for UTI should translate into more effective care 
for patients, less frustration and speculation on the part of providers, and an overall reduction in 
antibiotic use.  
 
Next-generation Therapeutics 
Put simply, UTI therapies are in need of innovation. For decades, finite courses of 
antibiotics have been prescribed for women with UTIs, often in the absence of culture data; such 
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empiric treatment is effective at resolving acute symptoms, but clearly fails to eliminate 
recurrence risk (2). In addition, the rise of multidrug-resistant uropathogens (e.g., (107)) 
mandates definitive therapeutic selection based on actual patient culture and susceptibility results 
and/or local and institutional antibiograms. As the rate of resistance development (especially 
among Gram-negative uropathogens) has overtaken the pace of new antibiotic development, 
fundamentally new approaches are needed (108). Further, prophylactic antibiotics are 
incompletely effective in preventing infection (109), and in one mouse study, subtherapeutic 
levels of ciprofloxacin were shown to augment murine UTI (110). To move forward in the 
therapeutic realm, we must extend our molecular understanding of both the pathogen and the 
host. Contemporary development of novel UTI therapeutics has focused on interfering with 
pathogen binding to bladder epithelium or other key pathogen processes; the development of 
vaccines based on bacterial components; and the modulation of host responses, specifically 
promoting exfoliation to eradicate chronically resident bacteria from the bladder.  
An emerging example in which basic biology of the host-pathogen interaction has 
informed therapeutics development is that of mannosides and pilicides, compound families 
which target in distinct ways the crucial step of bacterial adherence to host cells. Pilicides 
interfere with the chaperone-usher pathway, preventing the assembly of adhesive pili on the 
bacterial surface and thereby abolishing epithelial binding (111, 112). In contrast, mannosides 
serve as competitive inhibitors, occupying the binding pocket of the type 1 pilus adhesin FimH 
with affinities that are orders of magnitude higher than those of the mannosylated uroplakins 
decorating the bladder epithelial surface (113). The oral bioavailability and efficacy of 
mannosides in preventing UTI in mice portend substantial potential utility in the clinic (114, 
115). Beyond uncomplicated cystitis, mannosides have also shown efficacy in mouse models for 
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prevention of catheter-associated UTI (as reflected by diminished bladder and catheter 
colonization) (116). Mannosides are being rationally optimized to exhibit more drug-like 
pharmacokinetic properties, such as improved metabolic stability and bioavailability (113, 117). 
Agents such as these, so-called “anti-virulence” compounds that block specific molecular steps 
in pathogenesis, apply much less selective pressure on pathogenic bacteria, thereby reducing the 
rate of resistance development (118). Further, due to their known mechanism of action, such 
agents can be used as tools to further probe the biology of host-pathogen interactions (119). 
Recent structural “snapshots” of bacterial pilus assembly via the chaperone-usher pathway (see 
Figure 3) may illuminate additional routes to inhibition (45, 120-123), with potentially much 
broader impact as this bacterial secretion pathway also underlies virulence factor production by 
diverse bacterial pathogens (e.g., Yersinia pestis). Direct application to the bladder luminal 
surface of nanoparticles, perhaps coated with the FimH adhesin (124), has also been explored in 
mice as a means to accomplish targeted delivery of novel therapeutics to the host (125).  
Successful vaccination against UPEC and other uropathogens could have monumental 
impact on the lives of those at risk for complicated UTIs or who suffer from recurring episodes. 
Multiple groups have worked to identify specific UPEC factors for potential use as vaccine 
antigens. Candidate antigens include the FimH adhesin, siderophores such as yersiniabactin 
(126), and other immunodominant proteins identified in mouse models (127, 128) (reviewed in 
(3, 44)). Two important considerations may hinder the effectiveness of vaccine candidates 
against UTI. First, as strains of E. coli (expressing type 1 pili, iron acquisition systems, and other 
factors) are present in the normal gut microbiota, vaccination could potentially alter the 
populations of proteobacteria in the gut. Second, as noted above, it is not clear how much 
antibody (IgG) in the healthy urinary tract should reach the bladder lumen. Therefore, elicitation 
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of serum antibodies against UPEC antigens may be more effective in preventing pyelonephritis, 
as antibodies may be more readily delivered to the kidney. Further studies into the correlates of 
adaptive immunity in both the upper and lower urinary tract are needed to advance these efforts. 
Another strategy for the management of acute or recurrent UTI may be to modulate or 
enhance host responses to UTI. As noted earlier, an exuberant inflammatory response 
predisposes the host to chronic cystitis (88, 98). In fact, in a mouse UTI model, inhibiting this 
response using an oral anti-inflammatory COX-2 inhibitor yielded better outcomes without 
actually targeting the bacteria (and thereby applying no selective pressure). These findings 
corroborated small clinical trials in women, in which symptomatic improvement at 4 and 7 days 
with ibuprofen alone was equivalent to oral antibiotics (129-131). Further, as the bladder 
exfoliation accompanying acute UPEC cystitis is not complete, bacteria within quiescent 
reservoirs may re-emerge to seed recurrent infection. Advanced, more efficacious exfoliants are 
being designed to unearth these quiescent reservoirs (132, 133). Once these bacteria are forced to 
emerge, they may be more susceptible to the actions of standard antibiotics. Therefore, combined 
exfoliant-antimicrobial strategies might rid the host of the UPEC reservoirs that underlie some 
recurrent UTIs (133). 
Finally, in considering updated UTI therapeutics, one must consider an impending 
paradigm shift regarding the “normal” state of the bladder – which has long been assumed to be 
sterile (134). Enhanced culture techniques, as well as metagenomics on catheter-collected 
samples, have detected urinary bacteria in the healthy and asymptomatic state in women (135). 
Interactions between these apparent commensals and soluble mediators such as antimicrobial 
peptides may alter susceptibility to UTI (136). Specific microbiome structures may also be 
related to conditions traditionally thought to be non-infectious, such as stress or urgency 
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incontinence (137, 138) and interstitial cystitis/chronic bladder pain. As the urinary microbiome 
becomes more extensively defined, we will have to account for it in considering the pathogenesis 
of UTI, as well as in choosing therapies for symptomatic patients.  
 
Emerging, Clinically Relevant Models for UTI 
Although many uncomplicated UTIs can resolve spontaneously or with antibiotic 
treatment, more complicated forms of UTI have not, until recently, been reflected in animal 
models. The majority of preclinical work in the last two decades on cystitis and pyelonephritis 
has relied on transurethral inoculation of UPEC into the bladder in female mice (139, 140). 
Emerging mouse models may enable additional clinically relevant questions to be addressed. 
 
Catheter-associated UTI (CAUTI) 
Prolonged urinary catheter usage is a risk factor for UTI, due largely to the ability of 
bacteria to establish a biofilm on the catheter that resists clearance by host defenses and 
antibiotics. CAUTIs represent the most common nosocomial infections and are associated with 
increased hospital length of stay, morbidity, and mortality (141, 142). As UPEC are less 
prominent in the epidemiology of CAUTI, other organisms such as Enterococcus faecalis have 
emerged as model organisms for study (7). Insertion of a urinary catheter elicits an inflammatory 
environment in the bladder, which is manifested histologically as exfoliation, edema of the 
lamina propria and submucosa, urothelial thinning, and mucosal lesions (7). This damaged 
mucosa and the catheter itself offer surfaces for bacterial adhesion (143). Recent data indicate 
that enterococcal adherence to urinary catheter material is mediated by fibrinogen, a host protein 
that is released into the bladder lumen and deposited on the catheter following insertion. E. 
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faecalis then bind fibrinogen via the pilus tip adhesin EbpA, subsequently forming a biofilm on 
the catheter (144, 145). These pathogenic events can be modeled in C57BL/6 mice in which a 
short length of silicone catheter material is transurethrally deposited in the bladder, followed by 
introduction of E. faecalis (143, 146). A structural understanding of bacterial adhesin association 
with catheter material and proteinaceous deposits may enable the design of new strategies to 
counteract catheter-associated UTI. 
 
Recurrent UTI 
Approximately 20-30% of women with acute cystitis go on to develop recurrent UTI 
(rUTI), and those who do suffer on average 2-3 additional UTIs in the year following an initial 
episode (2). The subsequent UTI might arise from reinoculation of the urethra with flora from 
the gastrointestinal tract, or from re-emergence of a bladder epithelial reservoir. In a genomic 
study, isolates from four patients with rUTI were analyzed by whole-genome sequencing (11). In 
two patients, the same UPEC clone dominated both gut and urinary tract habitats at the initial 
and subsequent infection; in the other two, a new clone had established dominance in both 
habitats at the time of recurrent UTI. Further, isolates causing subsequent UTI in these patients, 
when introduced into mice and compared with their initial infecting strain, exhibited increased 
fitness in both the gut and the urinary tract, demonstrating that fitness in these two important 
niches is not mutually exclusive (11). More recent models of gut colonization by UPEC may 
illuminate the movement of uropathogens from one body site to another and suggest strategies to 
eliminate UPEC from the gut as a route to preventing recurrent UTI (147). 
In a newly developed mouse model of rUTI, the C3H mouse strain – known to feature 
vesicoureteral reflux, a major risk factor for upper-tract UTI in humans (148) – can be sensitized 
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to later infection. Following an initial infection (experimentally resolved by treatment with 
antibiotics) and upon subsequent re-challenge with a later infection, these “sensitized” mice were 
more likely than naïve mice to suffer persistent bacteriuria and chronic cystitis (88). A leading 
hypothesis for recurrent UTIs is that an exuberant inflammatory response to initial infection 
causes bladder remodeling that predisposes the host to recurrent infection or more inflammatory 
outcomes (4, 88, 98, 142). This model may enable a mechanistic understanding of apparent 
predisposition to recurrent infection, in turn informing therapies that could interfere with or 
dampen this process. 
 
Male and Complicated UTI 
The higher prevalence of UTI in females is chiefly attributed to anatomic factors in 
women, such as shorter urethral length, shorter distance from the anus to urethral meatus, and 
permissiveness of the vaginal and perineal environments to microbial colonization (13, 142). 
However, males at both ends of the age spectrum (mainly infants <1 year of age and elderly men 
with prostatic hypertrophy) exhibit a higher incidence of UTI, and other conditions in males 
(diabetes, spinal cord injury, catheter use) also promote UTI (149). Among individuals with 
upper-tract UTI (pyelonephritis), males exhibit greater morbidity and mortality than females 
(150), suggesting that non-anatomical differences may be at work in these more severe 
infections. Further, there is a higher UTI incidence in women with polycystic ovary syndrome (a 
common hyperandrogenic state), and this risk normalizes upon antiandrogen treatment (151-
153), implicating a role for androgens in UTI risk in females as well. 
Until recently, essentially all cystitis and pyelonephritis studies have been performed in 
female mice, as the male mouse bladder has not been reliably accessible by catheter. Of note, 
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instillation of uropathogens into the urethra of male mice elicits prostatic infection (154-156). In 
a recently developed model of UTI, a small abdominal incision is made and bacteria are 
inoculated via needle into the bladders of male and female mice, permitting direct sex 
comparisons (157). This inoculation method recapitulates the IBC cascade of acute cystitis 
established in studies with catheter-infected females. Interestingly, once anatomic barriers are 
bypassed in this way, male mice experience more severe infection than females, mirroring 
epidemiologic data observed clinically in men; indeed, male C3H mice uniformly develop severe 
pyelonephritis and renal abscesses that are seen much less frequently in female mice (Figure 4) 
(157). Further, this susceptibility to pyelonephritis was potentiated in androgenized, catheter-
infected female mice (158). Of note, within the abscesses of male C3H/HeN mice, UPEC formed 
dense, biofilm like bacterial communities termed kidney bacterial communities (KBCs) (158). 
These KBCs are thought to contribute to the pathogenesis of upper-tract UTI (see Chapter 2). 
Nonsurgical inoculation techniques for male mice have also been advanced recently (156, 159). 
These new models open doors to study sex differences in UTI pathogenesis and host response, as 
well as sequelae of severe pyelonephritis and abscess formation; these latter phenotypes are 
relevant to febrile UTI in children, following which renal scarring is a common complication.  
 
Concluding Remarks 
Urinary tract infections continue to be among the most common bacterial infections in 
humans, eliciting millions of antibiotic prescriptions annually. Available therapies have not 
evolved significantly in recent years, do not prevent recurrences, and are challenged by rising 
antibiotic resistance. Creative approaches to treatment, including the development of anti-
virulence therapeutics, should be prioritized. In addition, the field lacks a thorough 
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understanding of protective host immunity related to UTI, if such is generated after natural 
infection (especially pyelonephritis) or can be elicited via vaccination. Given the broad range of 
organisms that can cause UTI and the unavoidable nature of some risk factors (e.g., urinary 
catheters), even highly effective novel interventions will not completely mitigate the impact of 
these infections on human health. However, the common pathogenic themes in Gram-negative 
community-onset UTI make this subset of infections a particularly important epidemiologic 
target.  
 
Conflicts of Interest 
D.A.H. serves on the Board of Directors of BioVersys AG, Basel, Switzerland. 
 
Acknowledgements 
This work was supported by the National Institutes of Health (P50-DK064540) and by 





Figure 1. Clinical features and virulence mechanisms in cystitis and pyelonephritis.  UTIs 
can present clinically in a variety of ways, most often reflecting cystitis (infection of the bladder) 
or pyelonephritis (infection of the kidney). Uropathogenic Escherichia coli (UPEC) are the most 
common cause of UTI (especially among community-onset infections), among other pathogens. 
Selected virulence factors associated with the pathogenesis of UPEC cystitis or pyelonephritis 
are shown and include adhesins, siderophores, toxins, siderophores, capsule, and other systems 




Figure 2. Various CUP pili present in UTI89, UPEC cystitis isolate.  Current known CUP pili 
encoded within the genome of UTI89 and their associated function. Perecentages represent 
percent of E. coli genomes containing the designated operons (47). Figure kindly provided by the 




Figure 3. Ribbon representation of the chaperone-adhesin-usher complex for assembly of 
type 1 pili from Escherichia coli.  The periplasmic chaperone FimC (green) delivers structural 
subunits to the outer membrane usher (FimD, red) for assembly. Subunits shown represent the 
pilus tip structure and include the adhesin FimH (purple) and adapters FimG (yellow, within the 
barrel of FimD) and FimF (gray). Each subunit has its immunoglobulin-like fold completed by a 
strand provided by the next subunit, in a process called donor-strand complementation (DSC). 
The energetic favorability provided by this final structure drives assembly on the periplasmic 




Figure 4. Tubular inflammation, dropout, and edema during severe Escherichia coli 
pyelonephritis in C3H/HeN male mice.  Gomori trichrome stain (photo from P. Olson; Trends 
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Females across the lifespan and certain male populations are susceptible to urinary tract 
infections (UTI). The influence of sex on UTI is incompletely understood, in part because 
preclinical modeling has been performed almost exclusively in female mice. Here, we employed 
established and new mouse models of UTI with uropathogenic Escherichia coli (UPEC) to 
investigate androgen influence on UTI pathogenesis. Susceptibility to UPEC UTI in both male 
and female hosts was potentiated with 5α-dihydrotestosterone, while males with androgen 
receptor (AR) deficiency and androgenized females treated with the AR antagonist enzalutamide 
were protected from severe pyelonephritis. In androgenized females and in males, UPEC formed 
dense intratubular, biofilm-like communities, some of which were sheltered from infiltrating 
leukocytes by the tubular epithelium and by peritubular fibrosis. Abscesses were nucleated by 
small intratubular collections of UPEC first visualized 5 days post infection and briskly 
expanding over the subsequent 24 h. Male mice deficient in Toll-like receptor 4, which fail to 
contain UPEC within abscesses, were susceptible to lethal dissemination. We conclude that AR 
activation imparts susceptibility to severe upper-tract UTI in both female and male murine hosts. 
Visualization of intratubular UPEC communities illuminates early renal abscess pathogenesis 
and the role of abscess formation in preventing dissemination of infection. In addition, our data 
suggest that androgen modulation may represent a novel therapeutic route to combat recalcitrant 







Bacterial infection of the urinary tract represents one of the most common human 
infectious diseases and imposes a large economic burden (1, 2). Ascension of uropathogens to 
the kidneys, resulting in pyelonephritis or urosepsis, is associated with mortality and threatens 
lifelong morbidity, including renal scarring and attendant risks of hypertension and chronic 
kidney disease, despite appropriate initial antibiotic treatment (3, 4). These contemporary 
challenges to the human host manifest in an era in which the primary causative agent of UTI, 
uropathogenic Escherichia coli (UPEC), displays unprecedented global prevalence and breadth 
of antimicrobial resistance (5).  
Preclinical modeling of severe pyelonephritis has been constrained by a lack of 
susceptible female murine models and technical inability to access the male mouse bladder via 
catheter (6, 7). To begin to decipher sex differences in UTI, we recently developed a minimally 
invasive surgical technique enabling direct bladder inoculation and comparison of UTI 
pathogenesis and outcomes in both male and female hosts. After equal intravesical inoculation 
with UPEC, male mice of multiple genetic backgrounds, compared with females, developed 
more severe renal infection – including extremely high kidney UPEC burdens and 90% prevalent 
renal abscess in male C3H/HeN mice (7). The C3H background is known to exhibit 
vesicoureteral reflux (VUR) (8) – a translationally relevant feature, as VUR is a major risk factor 
for upper-tract UTI, particularly in affected children. Micro- and macroscopic abscess formation 
is a pathological feature of pyelonephritis in humans (9), and the severity of inflammation 
correlates with subsequent renal scarring in several models of renal injury (10, 11).   
We previously reported that castration of male C3H/HeN mice prior to induction of UTI 
mitigated the development of chronic cystitis, severe pyelonephritis, and renal abscess, while 
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ovariectomy had no effect on these outcomes in females. Exogenous testosterone replacement in 
castrated male mice restored severe UTI phenotypes (7). It remained unknown if androgen-
driven UTI susceptibility extends to females, in whom UTI is much more prevalent overall (1, 
12, 13). Here, we used specific androgen receptor (AR) agonists and antagonists as well as 
genetic models to conclusively demonstrate the involvement of AR activation in susceptibility to 
UTI in both female and male hosts. The androgenized phenotypes enabled us to detail the 
formation of intratubular UPEC communities – dense, biofilm-like bacterial masses filling 
multiple tubular segments at the center of developing abscesses. These UPEC communities were 
sheltered from intense neutrophilic infiltrates by intact tubular epithelia, which exhibited 
peritubular fibrosis. Mice lacking functional TLR4 (the innate immune sensor of bacterial 
lipopolysaccharide) failed to contain UPEC within abscesses and were prone to mortality from 
urosepsis. These experiments reveal the importance of androgen exposure in UTI susceptibility 
across both host sexes, and enable the future dissection of niches and mechanisms exploited by 
UPEC for growth and persistence in the kidney during pyelonephritis and renal abscess 
formation. 
 
Materials and Methods 
Bacteria 
Uropathogenic E. coli strain UTI89, a type 1-piliated clinical cystitis isolate (14), was 
grown in static Luria-Bertani (LB) broth for 16-18 h at 37°C. Cultures were centrifuged for 10 
min at 7,500 × g at 4 °C before resuspension in sterile phosphate-buffered saline (PBS) to a final 
density of ~4 × 108 CFU/mL. 
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Surgical and catheterization murine models of UTI 
All animal protocols received prior approval from the Washington University 
Institutional Animal Care and Use Committee. Experiments were conducted in C3H/HeN 
(Envigo, Indianapolis, IN), C3H/HeJ, C57BL/6 Aw-J/Aw-J (or its isogenic Tfm mutant), or 
C57BL/6 (all from Jackson Laboratories, Bar Harbor, ME) strains. Mini-surgical bladder 
inoculations were carried out as described previously (7). Mice aged 8-9 wk were anesthetized 
with inhaled 3% isoflurane, and the abdomen was shaved and sterilized with 2% chlorhexidine 
solution. A 3-mm longitudinal, midline incision was made over the bladder through the skin and 
peritoneum. The bladder was aseptically emptied before injection of 50 µL containing 1-2 × 107 
CFU into the bladder lumen over 10 s. The bladder was allowed to expand for an additional 10 s 
before the needle was removed, and the peritoneum and skin were closed with sutures. Certain 
female-only experiments, as indicated, were replicated with bladder inoculation by catheter (15-
17).  
 
Castration and androgen treatment 
For surgical castration, male mice aged 4 wk received preoperative subcutaneous 
buprenorphine SR (0.05 mg/kg) prior to inhaled 3% isoflurane anesthesia. The scrotum was 
depilated with Nair (Church & Dwight Co., Ewing, NJ) and the operative field was disinfected 
with 2% chlorhexidine solution. A 1-cm ventral, midline incision was made in the scrotum, the 
tunica was pierced, and the testis and vas deferens were mobilized. The spermatic cord on each 
side was clamped and ligated with 4-0 Vicryl above the epididymis, and the testis and vas 
deferens were removed. The skin incision was closed with Vetbond (3M Animal Care Products, 
St. Paul, MN). Four days following castration or sham operation, 60-day extended-release pellets 
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containing 25 mg testosterone, 25 mg DHT, or placebo (Innovative Research of America, 
Sarasota, FL) were implanted in sterile fashion at the posterior neck, using a small incision and 
blunt dissection to create a subcutaneous pocket. UTI was induced 4 weeks later (i.e., at 8-9 wk 
of age).  
 
Antiandrogen treatment 
Female C57BL/6 mice, 5 weeks of age, received subcutaneous DHT or placebo pellets as 
described above. Beginning 3 d later, mice received enzalutamide 50 mg/kg daily for 6 d per wk 
by oral gavage, or vehicle (1% carboxymethylcellulose, 0.1% Tween-80, 5% DMSO). Ten days 
later, UTI was induced via catheter inoculation, as described above. Treatment continued until 
sacrifice 2 wpi.  
 
Serum analyte measurements 
Blood was collected by submandibular puncture, retroorbital aspiration, or cardiac 
puncture (if collection was coincident with euthanasia) into Microtainer serum separation tubes 
(Becton Dickinson, Franklin Lakes, NJ). Samples were allowed to clot for 90 min at room 
temperature (RT) before centrifugation at 10,000 × g. Serum testosterone was measured by 
enzyme immunoassay at the Ligand Assay and Analysis Core, University of Virginia Center for 
Research in Reproduction (Charlottesville, VA). Blood urea nitrogen (BUN) was measured by 





Determination of urine and tissue bacterial loads  
Where indicated, we obtained post-infection, clean-catch urine samples using gentle 
suprapubic pressure to enumerate CFU/mL urine. At the indicated time points, mice were 
euthanized via CO2 asphyxiation, and bladders and kidney pairs were aseptically removed and 
homogenized in 1 ml or 0.800 ml sterile PBS, respectively. To ascertain prostate bacterial loads, 
the male urogenital system was removed en bloc and the prostate was micro-dissected under a 
dissecting microscope as previously described (18). Serial dilutions of tissue homogenates or 
urine were plated on LB agar to enumerate bacterial loads. Where indicated, cystitis in C3H/HeN 
mice was classified as “chronic” if all urine and endpoint bladder titers contained >104 CFU/mL.  
 
Tissue histopathology, immunofluorescence, and immunohistochemistry 
Infected bladders and kidneys were bisected and fixed in 10% neutral buffered formalin 
for 24 h. Fixed tissues were embedded in paraffin, sectioned, and stained with H&E or Gomori 
trichrome. Alternatively, kidneys were frozen, sectioned with a cryostat, and similarly stained. 
For immunofluorescence, unstained slides were deparaffinized in xylenes and rehydrated in 
isopropanol, washed in water, and boiled in 10 mM sodium citrate. Slides were blocked in 1% 
BSA, 0.3% Triton-X 100 in PBS for 30 min at RT, and incubated with rabbit anti-E. coli 
antibody (E3500-06C, US Biological, Salem, MA) for 1 h at RT or overnight at 4 °C. After 
washing in PBS, sections were stained with AlexaFluor 488-conjugated goat anti-rabbit IgG 
(Life Technologies, Grand Island, NY) and SYTO 61 red fluorescent nucleic acid stain 
(Molecular Probes, Eugene, OR). Images were acquired on an Olympus FV1200 confocal 
microscope. For immunohistochemistry, unstained slides were deparaffinized in xylenes, 
rehydrated in a series of ethanol washes, boiled in 10mM sodium citrate, and blocked in 1% 
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BSA, 0.3% Triton-X 100 in PBS for 1 h at RT. Slides were incubated with rat anti-Ly6G 
antibody (BE0075-1, BioXCell, West Lebanon, NH) for 2 h at RT, then stained with biotinylated 
goat anti-rat IgG (BA-9400, Vector Laboratories, Burlingame, CA) for 1 h at RT; or incubated 
with rabbit anti-AR antibody (ab74272, Abcam, Cambridge, MA) for 2 h at RT, followed by 
biotinylated goat anti-rabbit IgG (BA-1000, Vector Laboratories) for 30 min at RT. For each 
target, slides were then treated for 30 min with Vectastain Elite ABC reagent and developed 
using DAB substrate kit (Vector Laboratories). Slides were then counterstained with 
hematoxylin, rehydrated, mounted, and visualized.  
 
Statistics 
Organ bacterial loads and numerical data were compared by the nonparametric Mann-
Whitney U test. Survival analysis was performed with the Mantel-Cox log-rank test. Fisher exact 
test was used for 2×2 comparisons. P values <0.05 were considered significant.  
 
Results 
Androgen exposure aggravates UTI severity in female C3H/HeN mice.  To test whether 
androgens could amplify UTI severity and enhance abscess development in female mice, as seen 
previously in males (7), we implanted slow-release subcutaneous testosterone or placebo pellets 
in female C3H/HeN mice 4 wk prior to mini-surgical bladder inoculation with UPEC. 
Testosterone pellet implantation significantly increased serum testosterone compared with 
placebo-treated females (Figure 1A), mirroring serum testosterone levels seen in males of 
similar age (19, 20). Multiple prior studies show that female C3H/HeN mice develop a bimodal 
distribution of bladder UPEC titers at 2-4 weeks post infection (wpi), whereby a minority (20-
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40%) of animals display chronic, active infection with ongoing inflammation and persistently 
high bladder bacterial loads while the majority of these females resolve infection (6, 7, 21). 
Consistent with these reports, a minority (36%) of placebo-treated females here exhibited 
chronic cystitis 2 wpi (i.e., bladder bacterial loads > 104 CFU; Figure 1B, circles). In contrast, 
64% of androgenized females exhibited chronic cystitis 2 wpi (Figure 1B, triangles). When CFU 
burdens were compared numerically, testosterone-treated females exhibited significantly higher 
bladder (P=0.0102) and kidney (P=0.002) bacterial loads 2 wpi compared to placebo-treated 
controls (Figure 1B). More strikingly, androgen exposure led to development of grossly visible 
renal abscess in 9 of 14 females (64%), compared to 0 of 14 placebo controls (P=0.0006). These 
data illustrate that elevated circulating testosterone predisposes to severe UTI independent of 
biological sex. Of note, while intravesical inoculation with UPEC does induce acute and chronic 
prostatitis in C3H/HeN males (Figure 2), our data in androgenized females exclude the prostate 
as a driver of androgen-induced severe UTI.  
 
Androgen receptor activation drives UTI severity.  We next aimed to identify the hormonal 
pathway(s) by which testosterone acts to induce severe UTI. Testosterone supplementation could 
perturb levels of other hormones in the hypothalamic-pituitary-gonadal (HPG) axis via its 
negative feedback on gonadotropin releasing hormone (GnRH), luteinizing hormone (LH), and 
follicle-stimulating hormone (FSH). In this scenario, increased GnRH, LH, and/or FSH could be 
protective in castrated males and non-androgenized females, while decreased secretion of these 
hormones in androgenized hosts could promote UTI susceptibility. Refuting this possibility, we 
previously found that while orchiectomy dramatically attenuated UTI, ovariectomy in females 
(which would activate the HPG axis similarly to castration in males(22)) had no influence on 
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UTI outcome (7). This finding, in conjunction with our ability to facilitate severe UTI in females 
via androgen treatment (Figure 1B), eliminates alteration in GnRH or gonadotropin levels as a 
mechanism for increased UTI severity in androgenized hosts. 
We next focused on the two canonical pathways of testosterone activity and relevant 
receptors. First, testosterone can undergo peripheral conversion by aromatase into estradiol, 
which could then activate the estrogen receptor. We therefore tested whether an aromatase-
resistant and (compared with testosterone) more potent and specific AR agonist, 5α-
dihydrotestosterone (DHT), would enhance UTI severity. We implanted slow-release DHT or 
placebo pellets 4 d after castration or sham operation in C3H/HeN males, then surgically infected 
mice 4 wk later. Consistent with our previous results, castration attenuated bladder (P=0.041) 
and kidney (P=0.0063) bacterial burdens 2 wpi in placebo-treated males (Figure 3A). Treatment 
with exogenous DHT reversed the effects of castration (Figure 3A), recapitulating the 
complementation seen with testosterone (7). Organ bacterial burdens in castrated, DHT-
complemented males were similar to those in sham-operated, placebo-treated males, with most 
animals in both groups developing bilateral renal abscess. Likewise, infection of DHT-treated 
female C3H/HeN mice led to significantly higher bladder bacterial burdens (P<0.0001) and 
frequency of chronic cystitis (87% vs 27%; P=0.0025) 2 wpi, compared with placebo-treated 
females (Figure 3B). DHT treatment also induced gross abscess formation in 73% of these 
females (vs 0% with placebo, P<0.0001) and dramatically increased kidney titers (Figure 3B, 
P<0.0001). Thus, peripheral aromatization of testosterone does not mediate susceptibility to 
severe UTI. Of additional note, in female-only experiments we replicated these results with 
UPEC inoculations via the traditional catheter route, demonstrating that the observed severe UTI 
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phenotypes and their androgen dependence are not attributable to the mini-surgical infection 
methodology. 
Independent of aromatization, androgens classically engage the AR, though alternative 
signaling pathways independent of AR have recently emerged (23, 24). We confirmed AR 
expression in both tubular epithelium and infiltrating leukocyte populations 2 wpi in male C3H 
kidneys (Figure 4). To demonstrate AR involvement in our observed phenotypes, we first 
adopted a genetic approach using C57BL/6 Aw-j testicular feminization (Tfm) mice, which encode 
a frameshift mutation disrupting the steroid-binding domain of the AR, rendering these animals 
insensitive to classical AR signaling (25, 26). Wild-type (WT) males exhibited kidney titers 
significantly higher than WT females (Figure 5A; P=0.016), as we previously observed (7). 
Importantly, the majority of Tfm males resolved renal infection (Figure 5A), with kidney 
bacterial burdens significantly lower than WT males (P=0.0043) but indistinguishable from WT 
females (P=0.50). The Tfm mutation did not have a significant effect on bladder bacterial loads 
24 hpi (Figure 6). 
We also demonstrated direct AR involvement via pharmacological inhibition with 
enzalutamide (27), a second-generation antiandrogen with higher potency and improved 
specificity over earlier agents (28, 29). We implanted C57BL/6 females with DHT or placebo 
pellets 2 wk prior to UTI, and 3 d later initiated enzalutamide or vehicle treatment. Enzalutamide 
administration conferred strong protection against severe UTI outcomes, with significantly 
reduced bacterial loads in the kidneys and bladder (P<0.0001 vs vehicle; Figure 5B, C). In total, 
these data specify that AR activation induces susceptibility to severe UTI in both host sexes and 
across multiple genetic backgrounds. 
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Severe upper-tract UTI in the androgenized host manifests as abscess nucleated by 
intratubular UPEC communities. As modeling of UTI has until now been limited to female 
mice, and females of most strains are resistant to severe pyelonephritis and renal abscess 
formation (6, 7, 30, 31), the field lacks a detailed understanding of the pathogenesis of ascending 
renal abscesses. However, the high incidence of abscess formation in androgenized C3H/HeN 
hosts (7) (Figure 1B, 3B) now allows interrogation of the anatomic and temporal details of 
abscess development following intravesical UPEC inoculation. Histological examination of 
kidneys 3 days post infection (dpi) from mice exhibiting urine and bladder bacterial titers >104 
CFU (predictive of pyelonephritis (7)) demonstrated only scant neutrophilic inflammation near 
the renal pelvis, with no visible abscess (Figure 7A) and no apparent tissue alteration in the renal 
cortex or medulla (Figure 7B). Visualized bacteria were limited to the renal pelvis and calyces 
(Figure 4C). By 5 dpi, a minority of infected mice (4 of 15, 27%; Figure 7A) exhibited gross 
abscess at necropsy. Sectioning of entire kidneys revealed infrequent small, intraluminal 
collections of bacillary UPEC distributed from the renal medulla (Figure 7D) to the cortex 
(Figure 7E, 8). The tubules housing these UPEC communities reflected cellular injury and were 
surrounded by small numbers of infiltrating neutrophils, without intraluminal inflammation 
(Figure 7E, F). By 6 dpi, 90% of infected males exhibited renal abscess at necropsy (Figure 7A, 
G), equivalent to the frequency observed 2 wpi (7). Thus, ascending renal abscesses in this 
model develop precipitously between 5 and 6 dpi, signifying rapid UPEC replication and 
neutrophil recruitment in this interval. 
Kidney sections from C3H/HeN males 2 wpi revealed UPEC populations in the centers 
of dense neutrophilic lesions appearing predominantly in the cortex (Figure 9A, 9B, 10). At this 
advanced stage, visible UPEC were located within the intratubular space, adopting 
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coccobacillary morphology in tightly packed communities (Figure 9B, C), in contrast to their 
more loosely associated appearance 5 dpi (Figure 7F). Recruited neutrophils had largely 
destroyed or replaced much of the surrounding tubular architecture (Figure 9A-D) and also 
formed casts within surrounding tubules (Figure 9E), as seen in human pyelonephritis and as 
reported in other mouse models (8, 32, 33). We often observed multiple, discrete intratubular 
bacterial collections in close proximity within the same neutrophilic lesion (Figure 9D), and at 
low power, parenchymal involvement distinctly followed a wedge-shaped pattern while remote 
areas of kidney were spared (Figure 9F). In conjunction with findings at earlier time points 
(Figure 7), and consonant with recently published data in C3H/HeOuJ mice (32), these results 
indicate that ascending UPEC colonize an individual papillary collecting duct pyramid and 
multiple interconnected nephrons via robust intraluminal replication to nucleate abscess 
formation within a given segment of the kidney. Consistent with our prior data (34), serum BUN 
was not significantly elevated in these C3H males 2 wpi (Figure 11). Additionally, abscesses 
rarely develop in non-androgenized female C3H/HeN mice (6, 7, 35), but we did identify an 
abscess with similar bacterial intratubular community morphology in one such mouse (out of 
>30 examined 2 wpi; Figure 12).  
 
Abscess formation prevents lethal dissemination but shelters UPEC intratubular 
communities.  In the abscessed region of kidney 2 wpi, renal parenchyma was largely replaced 
by intense neutrophilic infiltrate (Figure 9). Light and fluorescence microscopy captured 
breaching of the UPEC-harboring tubules by neutrophils (Figure 13A, B), and trichrome 
staining of male C3H/HeN kidneys 2 wpi indicated that the infected tubules were fibrotic 
(Figure 13C, D). These findings suggest that for at least some duration, the tubular structure and 
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subsequent UPEC-provoked peritubular fibrosis shield the intratubular UPEC community from 
phagocytic attack.  
It was previously reported that mice with functional deficiency of Toll-like receptor 4 
(TLR4), which exhibit markedly delayed and diminished innate responses to UTI (36, 37), do 
not develop renal abscesses even following direct renal injection of UPEC (6, 38, 39). We 
therefore tested how TLR4 deficiency would impact sex differences in ascending renal infection 
by surgically infecting male and female C3H/HeJ mice, isogenic with C3H/HeN except for a 
TLR4 mutation that renders HeJ mice insensitive to lipopolysaccharide (40). Most infected 
C3H/HeJ females survived through the period of observation, while many infected C3H/HeJ 
males succumbed to infection between 3 and 7 dpi (P=0.0274; Figure 14A). Interestingly, the 
timing of demise in these C3H/HeJ males coincided with the window of abscess development we 
observed in C3H/HeN males (Figure 7). Abscess was not observed in C3H/HeJ males at 
necropsy despite the presence of intratubular UPEC communities (Figure 14B). In addition, at 3 
dpi (preceding any deaths), infected male C3H/HeJ mice displayed significantly higher renal 
(P=0.001) and bladder (P=0.001) bacterial burdens compared to female C3H/HeJ mice (Figure 
14C).  
These outcomes in C3H/HeJ males are in sharp contrast to infected C3H/HeN males, 
which uniformly survive despite persistence (for at least 20 wpi) of high renal bacterial burdens 
and abscesses (34). To further assess the cause of this sex difference in mortality, we infected 
male or female C3H/HeN mice and cultured spleen, liver and blood 3 dpi (preceding any deaths). 
Dissemination of infection was significantly more prevalent in males, as reflected by higher 
bacterial loads in spleen (P<0.001), liver (P<0.001), and blood (P<0.05) (Figure 14D). 
Persistence of observed sex differences in UTI outcomes in the absence of functional TLR4 
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suggests that these differences are not attributable to androgen effects on TLR4 signaling, 
expression, or activation. Collectively, these data support a model in which abscess formation 
with peritubular fibrosis enables the immunocompetent host to contain renal infection and 
prevent lethal systemic disease; however, this host strategy also permits UPEC to maintain a 




In this study, we show that AR activation in either host sex underlies increased 
susceptibility to pyelonephritis and renal abscess formation, a paradigm with significant 
translational implications. We further demonstrate that UPEC establishes intraluminal 
communities within kidney tubules, arising rapidly in the androgenized host within a narrow 
temporal window to nucleate nascent renal abscesses. A subset of these kidney bacterial 
communities (KBCs) were protected from phagocytosis, as the fibrotic tubular epithelium 
encapsulating these communities appeared to hinder phagocyte entry.  
Abscesses were focal or multifocal, occurring within regions of pyelonephritis that 
followed the pattern of a collecting duct unit (32) and located adjacent to other, uninvolved 
segments of renal parenchyma. This observation suggests that among UPEC that reach the renal 
pelvis, only a fraction are ultimately successful in accessing and persisting within selected 
nephrons. Beyond the process of uropathogen ascension through the urethra or from the bladder 
to the kidney, it is equally important to illuminate this “third ascension” of uropathogens from 
the renal pelvis and calyces to more proximal segments of the nephron. Although some studies 
have implicated immunologic factors influencing ascension and persistence in the collecting duct 
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(41-43), the virulence mechanisms and host factors which enable tubular ascension and 
intraluminal replication are incompletely defined.   
Even in a single micrograph of a developing abscess, one can see areas of complete 
destruction of cortical and tubular architecture, infected tubules that have been invaded partially 
or completely by neutrophils (consistent with neutrophil casts seen in other recent studies (8, 
32)), and intratubular KBCs that have not yet been successfully breached by phagocytes. These 
persisting KBCs are apparently shielded for a more prolonged time by tubular epithelium and 
peritubular fibrosis. These images thus offer snapshots of various stages of the infiltration and 
phagocytic activity of host immune cells en route to a fully formed abscess. In other disease 
models, including ischemic kidney injury, transmigration of neutrophils across the tubule 
epithelium appears to be unimpaired (44-46). Fruitful future investigations in the present model 
will illuminate pathogen strategies or host factors (e.g., local ischemia (47, 48), anatomic 
features such as the basement membrane, or specific cellular programs that promote post-
infection fibrosis) that impede neutrophil migration into the abscess community. Importantly, 
while male C3H/HeN mice are unable to resolve renal infection, their survival indicates that 
abscess formation successfully restricts the dissemination of infection. In contrast, congenic 
males with impaired innate responses fail to form abscesses surrounding bacterial communities 
and ultimately succumb to disseminated infection. We therefore propose a model whereby the 
pathology of abscess formation is a double-edged sword: bacteria are contained via inflammation 
and fibrosis, preventing overwhelming systemic disease, but some tubules represent a privileged 
site for bacterial replication where, at least for a time, phagocytes within the abscess lesion are 
unable to readily access the expanding UPEC community.  
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These KBCs display notable parallels to earlier descriptions of intracellular bacterial 
communities within bladder epithelium (49-52), though the microenvironment is presumably 
quite different in these two niches. The thematic similarity of UPEC community morphology in 
bladder and kidney hints that UPEC may use conserved programming to proliferate and to 
ultimately subvert the innate cellular response through biofilm formation within these niches 
(53). Beyond the recognized advantage of biofilms in limiting antibiotic diffusion, the location of 
KBCs also likely impairs antibiotic action, perhaps by occluding local transit of antibiotics in the 
urinary space, inducing restriction of blood flow to UPEC-infected areas (47, 48), or limiting 
diffusion from the blood space through injured and fibrotic tubular epithelia. These features 
correlate with the clinical need for prolonged antibiotic therapy in severe pyelonephritis and 
renal abscess.  
AR activation clearly induced susceptibility to severe pyelonephritis and abscess 
development in both host sexes; genetic or pharmacologic inhibition of AR signaling attenuated 
severe UTI. Further investigations will specify the AR-regulated gene networks that mediate UTI 
susceptibility in androgenized hosts, in renal epithelium and/or local or circulating immune cells. 
Androgen signaling has been implicated in immune cell function in other systems. For example, 
monocyte migration and production of TNFα were amplified by androgen exposure in a mouse 
model of wound healing (54); overall, mouse models and in vitro studies of neutrophils and 
macrophages have not yet painted a complete and unified picture regarding androgen influence 
(55-58). Further, the persistence of a sex difference in C3H/HeJ mice, which lack functional 
TLR4 (the primary instigator of inflammatory responses in the kidney), suggests that the effect 
of androgens on UTI pathogenesis does not reside entirely in the hematopoietic compartment.  
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We previously saw no appreciable phenotype following estrogen depletion (7), and here 
have ruled out a contribution from peripheral aromatization. This is in contrast to a current 
paradigm, supported by some human and mouse studies, in which estrogen levels are believed to 
influence UTI pathogenesis (59-63). Instead, we argue that even modest elevations in circulating 
testosterone (which often parallel increases in estradiol (64-66)) in female and susceptible male 
patients may have a greater effect on frequency or severity of UTI. Certainly, the human 
population with the highest circulating testosterone, adolescent males (67), exhibit the lowest 
rates of UTI (12), but the urogenital anatomy (compared with that of women) comprises the key 
defense against UTI in otherwise healthy men (7). In fact, when these anatomic barriers are 
compromised or bypassed, epidemiologic data reflect increased morbidity and mortality in men 
who do develop complicated UTI, as compared with women (68-71). In a related vein, male 
infants (e.g., those under 6 months of age) presenting with UTI outnumber their female 
counterparts, with male UTI rates falling steadily from the neonatal period to late infancy (72-
80). This epidemiologic phenomenon closely parallels the postnatal surge in testosterone in male 
infants that reaches pubertal levels shortly after birth, then steadily wanes to a prepubertal 
baseline by 6-9 months of age (81-84). Thus, while UTI risk in male infants is commonly 
ascribed to indistinct “urodynamic immaturity,” we speculate that testosterone activity may 
actually underlie this risk, especially in the two thirds of such infants who (after first febrile UTI) 
lack demonstrable VUR or obstruction (85). 
The present finding that androgen-mediated UTI receptivity affects females (as well as 
males) extends the translational implications of our work. In murine models of polycystic 
ovarian syndrome (PCOS; a common hyperandrogenic state in young women), mice 
overexpressing LH (and consequently testosterone) develop spontaneous pyelonephritis and 
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associated renal damage (86-89). Most clinical studies of PCOS have not specifically ascertained 
UTI incidence in these women; however, where data are available, women with PCOS exhibited 
increased UTI rates compared to healthy females (90-92), and these rates fell in affected women 
following antiandrogen therapy (90). An untold number of women without overt 
hyperandrogenism might be at higher UTI risk because of circulating testosterone levels near the 
upper limits of the “normal” range, a potential causative relationship that mandates further study. 
We present proof of concept that the course of severe UTI can be mitigated by AR antagonism, 
suggesting that antiandrogen therapy may represent an avenue for adjunctive therapy in 
treatment-refractory cases of complicated UTI.  
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Figure 1. Androgen exposure aggravates UTI severity in females.  Female C3H/HeN mice 
were subcutaneously implanted with placebo (filled circles) or long-release testosterone pellets 
(filled triangles) 4 wk prior to induction of UTI. Testosterone was measured via enzyme 
immunoassay at time of infection; each sample was measured in duplicate and recorded as the 
mean. As anticipated, testosterone pellets increased the serum testosterone to levels 
physiologically relevant to normal males (A, ***P<0.0001 vs placebo). Organ harvest 2 wpi (B) 
revealed higher bacterial loads in C3H/HeN females receiving testosterone, in both the bladders 




Figure 2. Male C3H/HeN mice develop continued prostrate infection after surgical bladder 
inoculation. Mini-surgical inoculation of the bladder with UPEC strain UTI89 in C3H/HeN 
males results in durable prostate infection. Shown are bacterial loads in homogenates of whole 
prostate harvested at the indicated time points (aggregate of 3 experiments with total n = 14-15 
per condition). Bars indicate geometric mean, and dotted line indicates limit of detection.   
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Figure 3. Testosterone influence on UTI severity is not mediated via aromatization.  
Bladder and kidney bacterial burdens were measured 2 wpi (A) in sham-operated C3H/HeN 
males treated with placebo pellets (open circles), castrated males treated with placebo pellets 
(open triangles), and castrated males receiving pellets of 5α-dihydrotestosterone (DHT), a potent 
androgen not susceptible to conversion to estrogen via the action of aromatase (inverted 
triangles). As seen previously, castration was protective against severe UTI (*P<0.041 in 
bladder, **P<0.0063 in kidney vs sham-operated). Treatment of castrated males with exogenous 
DHT reversed this effect (***P<0.0001 in both organs vs castrated males receiving placebo); 
DHT-complemented males exhibited organ bacterial burdens equivalent to sham-operated, 
placebo-treated males (A) and similarly developed gross renal abscess. (B) In an analogous way, 
treatment of C3H/HeN females with DHT prior to initiation of UTI was associated with 
significantly higher bladder and kidney bacterial burdens 2 wpi (***P<0.0001 vs placebo). 
Dotted lines indicate limit of detection.  
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Figure 4. The androgen receptor is expressed on epithelial and hematopoietic cells in 
infected male C3H/HeN kidneys.  Immunohistochemistry demonstrates androgen receptor 
(AR) expression by both epithelial and hematopoietic cells in the infected kidney. AR staining of 
(A) an uninflamed area and (B) a heavily inflamed area of UPEC-infected kidney in a C3H/HeN 
male 2 wpi shows expression in most epithelial cells, particularly in the nuclei, and in most of 
the infiltrating leukocytes. Panels (C) and (D) represent control images of similar areas of 
kidney, with hematoxylin counterstain but with no primary antibody. Scale bar in lower right, 50 
µm, applies to all images.   
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Figure 5. Androgen receptor activation enhances severity of UTI.  (A) Renal bacterial loads 
2 wpi in genotypes comprising males (open circles) or females (filled circles). Included strains 
are WT males (AR+/Y), androgen receptor-deficient (Tfm) males (ARTfm/Y), and WT females 
(AR+/+). The renal bacterial loads of functionally AR-deficient (TFM) males were significantly 
lower than in WT males (**P<0.01) and were equivalent to those in WT females. In fact, the 
kidneys of most AR-deficient males were sterile 2 wpi (below the limit of detection, indicated by 
the dotted line). (B, C) Female C57BL/6 mice were implanted 2 wk prior to infection with a 
long-release subcutaneous pellet of DHT or placebo; 3 d later (11 d prior to infection), oral 
gavage with enzalutamide (Enz) or vehicle (Veh) was initiated and continued until sacrifice 2 
wpi.  As observed in C3H mice (Figures 1 and 2), DHT treatment of C57BL/6 females conferred 
susceptibility to severe UTI, as evidenced by significantly higher bladder (B) and kidney (C) 
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bacterial loads 2 wpi compared with non-androgenized females (**P<0.01). In addition, 
treatment of DHT-treated mice with Enz sharply reduced bacterial loads in both bladder and 




Figure 6. In C57BL/6 mice, bladder titers are not significantly impacted by the Tfm 
mutation.  Bladder bacterial loads in C57BL/6 mice with the indicated genotypes. In contrast to 




Figure 7. Timeline of renal abscess formation in C3H/HeN mice. (A) Proportion of male 
C3H/HeN mice exhibiting gross abscess formation at necropsy at the indicated intervals (n = 8-
15 per time point). At 3 dpi, histology demonstrates normal renal architecture (B) and bacteria 
within the renal pelvis (C). At 5 dpi, immunofluorescence and H&E staining identify small 
collections of bacillary UPEC in the urinary space from the medulla (D; anti-E. coli green) to the 
cortex (E, F; anti-E. coli green in E inset). By 6 dpi, histologic evidence of abscess is fully 
established, with necrotic lesions, loss of tubular architecture and replacement by neutrophilic 
infiltrate (G, arrowheads). Scale bars: B, 100 µm; C, 50 µm; D, 25 µm; E, 100 µm; F, 20 µm; G, 
200 µm.   
74 
 
Figure 8. Bacillary UPEC colonize tubules and form developing colonies 5 dpi.  At 5 dpi in 
infected C3H/HeN males, immunofluorescence microscopy demonstrates bacillary UPEC 




Figure 9. UPEC establish biofilm-like communities in a protected intraluminal niche.  
Neutrophilic abscesses were seen 2 wpi predominantly in the cortex (A), centered on a nidus of 
infected tubules (examples at A arrowheads, and B). Infected tubules at this time point were 
filled with coccobacillary UPEC, as seen by immunofluorescence with anti-E. coli antibodies 
(green in C; host nuclei are stained red). In many infected kidneys, multiple infected tubules 
were identified within a single large abscess lesion (D). The lumina of some tubules were 
occupied by neutrophil casts (E). Overall, the pattern of inflammation followed that of a wedge 
of nephrons associated with an infected papillary collecting duct (duct of Bellini), generally 
outlined by the gray dashed lines in (F). Scale bars: A, 200 µm; B, 50 µm; C, 25 µm; D, 50 µm; 
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E, 25 µm; F, 200 µm. 
 
Figure 10. The infiltrate within renal abscesses is composed primarily of neutrophils.  The 
cellular infiltrate surrounding kidney bacterial communities within renal abscesses observed 2 
wpi in UPEC-infected C3H/HeN males is comprised predominantly of neutrophils (left panel), 
as revealed by immunohistochemistry with anti-Ly6G antibody. An uninvolved area of the same 




Figure 11. Serum BUN measurements show no difference between infected and mock-
infected mice.  Serum BUN measurements pre-inoculation (Pre), 7 dpi, and 14 dpi in C3H/HeN 
males infected via mini-surgical bladder inoculation with UPEC strain UTI89 or mock infected 
with PBS (Mock). No significant differences were observed. All males shown here had high-titer 
pyelonephritis with abscess at 14 dpi (data not shown). In prior published work (34), infected 




Figure 12. Abscess within female C3H/HeN mice.  Abscess identified 2 wpi in a single non-
androgenized female C3H/HeN mouse, demonstrating an H&E appearance analogous to 
abscesses seen in a majority of male C3H/HeN mice. Features include intratubular UPEC 
communities separated by tubular epithelia from intense neutrophilic infiltrate, which has 




Figure 13. Tubular epithelium and peritubular fibrosis restrict infection but protect UPEC 
from infiltrating phagocytes.  The process by which tubular architecture is destroyed within the 
abscess by 2 wpi in C3H/HeN males was captured in images showing infiltrating neutrophils 
breaching the epithelium of tubules harboring UPEC communities (A, H&E; B, anti-E. coli in 
green, nuclear stain in red). Gomori trichrome staining 2 wpi revealed that infected tubules were 
fibrotic (C), compared with kidneys from mock-infected C3H/HeN males at the same time point 




Figure 14. UPEC-infected TLR4-deficient males fail to form renal abscesses and are 
vulnerable to lethal dissemination.  (A) Neutrophil recruitment and abscess formation were 
necessary for containment of infection; when the TLR4-deficient C3H/HeJ strain was used, male 
mice were much more likely to succumb to infection (n=10 per group, *P=0.0274), an outcome 
not seen in immunocompetent C3H/HeN mice. Surviving C3H/HeJ males failed to form 
abscesses surrounding UPEC-infected tubules (B; scale bar, 20 µm). Male C3H/HeJ mice 
developed significantly higher bladder and kidney titers than females 3 dpi (C, ***P=0.001). In 
addition, male C3H/HeJ mice were significantly more susceptible than females to dissemination, 
the likely cause of death, as evidenced by bacterial loads 3 dpi in spleen, liver and blood (D, 




1. Foxman B, Brown P. 2003. Epidemiology of urinary tract infections: transmission and 
risk factors, incidence, and costs. Infect Dis Clin North Am 17:227-41. 
2. Rosenberg M. 1999. Pharmacoeconomics of treating uncomplicated urinary tract 
infections. Int J Antimicrob Agents 11:247-51; discussion 261-4. 
3. Jacobson SH, Eklöf O, Eriksson CG, Lins LE, Tidgren B, Winberg J. 1989. Development 
of hypertension and uraemia after pyelonephritis in childhood: 27 year follow up. Brit 
Med J 299:703. 
4. Levey AS, Coresh J. 2012. Chronic kidney disease. Lancet 379:165-180. 
5. Zowawi HM, Harris PN, Roberts MJ, Tambyah PA, Schembri MA, Pezzani MD, 
Williamson DA, Paterson DL. 2015. The emerging threat of multidrug-resistant Gram-
negative bacteria in urology. Nat Rev Urol 12:570-84. 
6. Hannan TJ, Mysorekar IU, Hung CS, Isaacson-Schmid ML, Hultgren SJ. 2010. Early 
severe inflammatory responses to uropathogenic E. coli predispose to chronic and 
recurrent urinary tract infection. PLoS Pathog 6:e1001042. 
7. Olson PD, Hruska KA, Hunstad DA. 2016. Androgens enhance male urinary tract 
infection severity in a new model. J Am Soc Nephrol 27:1625-34. 
8. Bowen SE, Watt CL, Murawski IJ, Gupta IR, Abraham SN. 2013. Interplay between 
vesicoureteric reflux and kidney infection in the development of reflux nephropathy in 
mice. Dis Model Mech 6:934-41. 
9. Schrier RW. 2007. Diseases of the kidney & urinary tract, 8th ed. Wolters Kluwer 
Health/Lippincott Williams & Wilkins, Philadelphia. 
82 
10. Anders HJ, Schaefer L. 2014. Beyond tissue injury-damage-associated molecular 
patterns, toll-like receptors, and inflammasomes also drive regeneration and fibrosis. J 
Am Soc Nephrol 25:1387-400. 
11. Suarez-Alvarez B, Liapis H, Anders HJ. 2016. Links between coagulation, inflammation, 
regeneration, and fibrosis in kidney pathology. Lab Invest 96:378-90. 
12. Foxman B. 2010. The epidemiology of urinary tract infection. Nat Rev Urol 7:653-60. 
13. Foxman B. 2003. Epidemiology of urinary tract infections: incidence, morbidity, and 
economic costs. Dis Mon 49:53-70. 
14. Chen SL, Hung CS, Pinkner JS, Walker JN, Cusumano CK, Li Z, Bouckaert J, Gordon 
JI, Hultgren SJ. 2009. Positive selection identifies an in vivo role for FimH during 
urinary tract infection in addition to mannose binding. Proc Natl Acad Sci U S A 
106:22439-22444. 
15. Hung CS, Dodson KW, Hultgren SJ. 2009. A murine model of urinary tract infection. 
Nat Protoc 4:1230-1243. 
16. Mulvey MA, Lopez-Boado YS, Wilson CL, Roth R, Parks WC, Heuser J, Hultgren SJ. 
1998. Induction and evasion of host defenses by type 1-piliated uropathogenic 
Escherichia coli. Science 282:1494-7. 
17. Hannan TJ, Hunstad DA. 2016. A murine model for Escherichia coli urinary tract 
infection. Methods Mol Biol 1333:159-75. 
18. Lukacs RU, Goldstein AS, Lawson DA, Cheng D, Witte ON. 2010. Isolation, cultivation, 
and characterization of adult murine prostate stem cells. Nat Protoc 5:702-713. 
83 
19. Angele MK, Ayala A, Cioffi WG, Bland KI, Chaudry IH. 1998. Testosterone: the culprit 
for producing splenocyte immune depression after trauma hemorrhage. Am J Physiol Cell 
Physiol 274:C1530-C1536. 
20. Brouillette J, Rivard K, Lizotte E, Fiset C. 2005. Sex and strain differences in adult 
mouse cardiac repolarization: importance of androgens. Cardiovasc Res 65:148-57. 
21. Nicholson TF, Watts KM, Hunstad DA. 2009. OmpA of uropathogenic Escherichia coli 
promotes postinvasion pathogenesis of cystitis. Infect Immun 77:5245-5251. 
22. Couse JF, Yates MM, Walker VR, Korach KS. 2003. Characterization of the 
hypothalamic-pituitary-gonadal axis in estrogen receptor (ER) null mice reveals 
hypergonadism and endocrine sex reversal in females lacking ERα but not ERβ. Mol 
Endocrinol 17:1039-1053. 
23. Walker WH. 2010. Non-classical actions of testosterone and spermatogenesis. Philos 
Trans R Soc Lond B Biol Sci 365:1557-1569. 
24. Rahman F, Christian HC. 2007. Non-classical actions of testosterone: an update. Trends 
Endocrinol Metab 18:371-378. 
25. Lyon MF, Hawkes SG. 1970. X-linked gene for testicular feminization in the mouse. 
Nature 227:1217-1219. 
26. Yeh S, Tsai M-Y, Xu Q, Mu X-M, Lardy H, Huang K-E, Lin H, Yeh S-D, Altuwaijri S, 
Zhou X. 2002. Generation and characterization of androgen receptor knockout (ARKO) 
mice: an in vivo model for the study of androgen functions in selective tissues. Proc Natl 
Acad Sci U S A 99:13498-13503. 
27. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, 
Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, 
84 
Scher HI, Jung ME, Sawyers CL. 2009. Development of a second-generation 
antiandrogen for treatment of advanced prostate cancer. Science 324:787-90. 
28. Fenton MA, Shuster TD, Fertig AM, Taplin ME, Kolvenbag G, Bubley GJ, Balk SP. 
1997. Functional characterization of mutant androgen receptors from androgen-
independent prostate cancer. Clin Cancer Res 3:1383-1388. 
29. Wong C-i, Kelce WR, Sar M, Wilson EM. 1995. Androgen receptor antagonist versus 
agonist activities of the fungicide vinclozolin relative to hydroxyflutamide. J Biol Chem 
270:19998-20003. 
30. Svensson M, Yadav M, Holmqvist B, Lutay N, Svanborg C, Godaly G. 2011. Acute 
pyelonephritis and renal scarring are caused by dysfunctional innate immunity in mCxcr2 
heterozygous mice. Kidney Int 80:1064-1072. 
31. Jaillon S, Moalli F, Ragnarsdottir B, Bonavita E, Puthia M, Riva F, Barbati E, Nebuloni 
M, Cvetko Krajinovic L, Markotic A, Valentino S, Doni A, Tartari S, Graziani G, 
Montanelli A, Delneste Y, Svanborg C, Garlanda C, Mantovani A. 2014. The humoral 
pattern recognition molecule PTX3 is a key component of innate immunity against 
urinary tractinfection. Immunity 40:621-632. 
32. Li B, Haridas B, Jackson AR, Cortado H, Mayne N, Kohnken R, Bolon B, McHugh KM, 
Schwaderer AL, Spencer JD, Ching CB, Hains DS, Justice SS, Partida-Sanchez S, 
Becknell B. 2017. Inflammation drives renal scarring in experimental pyelonephritis. Am 
J Physiol Renal Physiol 312:F43-f53. 
33. Stamm WE. 1983. Measurement of pyuria and its relation to bacteriuria. Am J Med 
75:53-58. 
85 
34. Olson PD, McLellan LK, Liu A, Briden KL, Tiemann KM, Daugherty AL, Hruska KA, 
Hunstad DA. 2017. Renal scar formation and kidney function following antibiotic-treated 
murine pyelonephritis. Dis Model Mech 10:1371-1379. 
35. Rosen DA, Hung CS, Kline KA, Hultgren SJ. 2008. Streptozocin-induced diabetic mouse 
model of urinary tract infection. Infect Immun 76:4290-8. 
36. Hagberg L, Hull R, Hull S, McGhee JR, Michalek SM, Svanborg Eden C. 1984. 
Difference in susceptibility to gram-negative urinary tract infection between C3H/HeJ 
and C3H/HeN mice. Infect Immun 46:839-44. 
37. Shahin RD, Engberg I, Hagberg L, Svanborg Eden C. 1987. Neutrophil recruitment and 
bacterial clearance correlated with LPS responsiveness in local Gram-negative infection. 
J Immunol 138:3475-80. 
38. Schilling JD, Mulvey MA, Vincent CD, Lorenz RG, Hultgren SJ. 2001. Bacterial 
invasion augments epithelial cytokine responses to Escherichia coli through a 
lipopolysaccharide-dependent mechanism. J Immunol 166:1148-55. 
39. Schilling JD, Martin SM, Hung CS, Lorenz RG, Hultgren SJ. 2003. Toll-like receptor 4 
on stromal and hematopoietic cells mediates innate resistance to uropathogenic 
Escherichia coli. Proc Natl Acad Sci U S A 100:4203-4208. 
40. Vogel SN, Johnson D, Perera PY, Medvedev A, Lariviere L, Qureshi ST, Malo D. 1999. 
Cutting edge: functional characterization of the effect of the C3H/HeJ defect in mice that 
lack an Lpsn gene: in vivo evidence for a dominant negative mutation. J Immunol 
162:5666-70. 
86 
41. Chassin C, Hornef MW, Bens M, Lotz M, Goujon JM, Vimont S, Arlet G, Hertig A, 
Rondeau E, Vandewalle A. 2007. Hormonal control of the renal immune response and 
antibacterial host defense by arginine vasopressin. J Exp Med 204:2837-52. 
42. Chassin C, Vimont S, Cluzeaud F, Bens M, Goujon JM, Fernandez B, Hertig A, Rondeau 
E, Arlet G, Hornef MW, Vandewalle A. 2008. TLR4 facilitates translocation of bacteria 
across renal collecting duct cells. J Am Soc Nephrol 19:2364-74. 
43. Paragas N, Kulkarni R, Werth M, Schmidt-Ott KM, Forster C, Deng R, Zhang Q, Singer 
E, Klose AD, Shen TH, Francis KP, Ray S, Vijayakumar S, Seward S, Bovino ME, Xu 
K, Takabe Y, Amaral FE, Mohan S, Wax R, Corbin K, Sanna-Cherchi S, Mori K, 
Johnson L, Nickolas T, D'Agati V, Lin CS, Qiu A, Al-Awqati Q, Ratner AJ, Barasch J. 
2014. α-Intercalated cells defend the urinary system from bacterial infection. J Clin 
Invest 124:2963-76. 
44. Joannidis M, Truebsbach S, Bijuklic K, Schratzberger P, Dunzedorfer S, Wintersteiger S, 
Lhotta K, Mayer G, Wiedermann CJ. 2004. Neutrophil transmigration in renal proximal 
tubular LLC-PK1 cells. Cell Physiol Biochem 14:101-12. 
45. Bijuklic K, Sturn DH, Jennings P, Kountchev J, Pfaller W, Wiedermann CJ, Patsch JR, 
Joannidis M. 2006. Mechanisms of neutrophil transmigration across renal proximal 
tubular HK-2 cells. Cell Physiol Biochem 17:233-44. 
46. Awad AS, Rouse M, Huang L, Vergis AL, Reutershan J, Cathro HP, Linden J, Okusa 
MD. 2009. Compartmentalization of neutrophils in the kidney and lung following acute 
ischemic kidney injury. Kidney Int 75:689-698. 
87 
47. Mansson LE, Melican K, Boekel J, Sandoval RM, Hautefort I, Tanner GA, Molitoris BA, 
Richter-Dahlfors A. 2007. Real-time studies of the progression of bacterial infections and 
immediate tissue responses in live animals. Cell Microbiol 9:413-24. 
48. Mansson LE, Melican K, Molitoris BA, Richter-Dahlfors A. 2007. Progression of 
bacterial infections studied in real time – novel perspectives provided by multiphoton 
microscopy. Cell Microbiol 9:2334-43. 
49. Rosen DA, Hooton TM, Stamm WE, Humphrey PA, Hultgren SJ. 2007. Detection of 
intracellular bacterial communities in human urinary tract infection. PLoS Med 4:e329. 
50. Rosen DA, Pinkner JS, Jones JM, Walker JN, Clegg S, Hultgren SJ. 2008. Utilization of 
an intracellular bacterial community pathway in Klebsiella pneumoniae urinary tract 
infection and the effects of FimK on type 1 pilus expression. Infect Immun 76:3337-45. 
51. Schwartz DJ, Chen SL, Hultgren SJ, Seed PC. 2011. Population dynamics and niche 
distribution of uropathogenic Escherichia coli during acute and chronic urinary tract 
infection. Infect Immun 79:4250-4259. 
52. Anderson GG, Palermo JJ, Schilling JD, Roth R, Heuser J, Hultgren SJ. 2003. 
Intracellular bacterial biofilm-like pods in urinary tract infections. Science 301:105-7. 
53. Olson PD, Hunstad DA. 2016. Subversion of host innate immunity by uropathogenic 
Escherichia coli. Pathogens 5:2. doi: 10.3390/pathogens5010002. 
54. Lai JJ, Lai KP, Chuang KH, Chang P, Yu IC, Lin WJ, Chang C. 2009. 
Monocyte/macrophage androgen receptor suppresses cutaneous wound healing in mice 
by enhancing local TNF-alpha expression. J Clin Invest 119:3739-51. 
88 
55. Chignalia AZ, Oliveira MA, Debbas V, Dull RO, Laurindo FR, Touyz RM, Carvalho 
MH, Fortes ZB, Tostes RC. 2015. Testosterone induces leucocyte migration by NADPH 
oxidase-driven ROS- and COX2-dependent mechanisms. Clin Sci 129:39-48. 
56. Chuang KH, Altuwaijri S, Li G, Lai JJ, Chu CY, Lai KP, Lin HY, Hsu JW, Keng P, Wu 
MC, Chang C. 2009. Neutropenia with impaired host defense against microbial infection 
in mice lacking androgen receptor. J Exp Med 206:1181-99. 
57. Fijak M, Schneider E, Klug J, Bhushan S, Hackstein H, Schuler G, Wygrecka M, 
Gromoll J, Meinhardt A. 2011. Testosterone replacement effectively inhibits the 
development of experimental autoimmune orchitis in rats: evidence for a direct role of 
testosterone on regulatory T cell expansion. J Immunol 186:5162-72. 
58. Filgueira FP, Lobato NS, DosSantos RA, Oliveira MA, Akamine EH, Tostes RC, Fortes 
ZB, Carvalho MH. 2012. Endogenous testosterone increases leukocyte-endothelial cell 
interaction in spontaneously hypertensive rats. Life Sci 90:689-94. 
59. Perrotta C, Aznar M, Mejia R, Albert X, Ng CW. 2008. Oestrogens for preventing 
recurrent urinary tract infection in postmenopausal women. Cochrane Database Syst Rev 
doi:10.1002/14651858.CD005131.pub2 
60. Lüthje P, Brauner H, Ramos NL, Övregaard A, Gläser R, Hirschberg AL, Aspenström P, 
Brauner A. 2013. Estrogen supports urothelial defense mechanisms. Sci Transl Med 
5:190ra80. 
61. Sonnex C. 1998. Influence of ovarian hormones on urogenital infection. Sex Transm Dis 
74:11-9. 
89 
62. Wang C, Symington JW, Ma E, Cao B, Mysorekar IU. 2013. Estrogenic modulation of 
uropathogenic Escherichia coli infection pathogenesis in a murine menopause model. 
Infect Immun 81:733-739. 
63. Stamm WE, Raz R. 1999. Factors contributing to susceptibility of postmenopausal 
women to recurrent urinary tract infections. Clin Infect Dis 28:723-5. 
64. Adly L, Hill D, Sherman ME, Sturgeon SR, Fears T, Mies C, Ziegler RG, Hoover RN, 
Schairer C. 2006. Serum concentrations of estrogens, sex hormone-binding globulin, and 
androgens and risk of breast cancer in postmenopausal women. Int J Cancer 119:2402-7. 
65. Kaaks R, Berrino F, Key T, Rinaldi S, Dossus L, Biessy C, Secreto G, Amiano P, 
Bingham S, Boeing H, Bueno de Mesquita HB, Chang-Claude J, Clavel-Chapelon F, 
Fournier A, van Gils CH, Gonzalez CA, Gurrea AB, Critselis E, Khaw KT, Krogh V, 
Lahmann PH, Nagel G, Olsen A, Onland-Moret NC, Overvad K, Palli D, Panico S, 
Peeters P, Quiros JR, Roddam A, Thiebaut A, Tjonneland A, Chirlaque MD, 
Trichopoulou A, Trichopoulos D, Tumino R, Vineis P, Norat T, Ferrari P, Slimani N, 
Riboli E. 2005. Serum sex steroids in premenopausal women and breast cancer risk 
within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl 
Cancer Inst 97:755-65. 
66. Braunstein GD, Johnson BD, Stanczyk FZ, Bittner V, Berga SL, Shaw L, Hodgson TK, 
Paul-Labrador M, Azziz R, Merz CNB. 2008. Relations between endogenous androgens 
and estrogens in postmenopausal women with suspected ischemic heart disease. J Clin 
Endocrinol Metab 93:4268-4275. 
67. Ross R, Bernstein L, Judd H, Hanisch R, Pike M, Henderson B. 1986. Serum testosterone 
levels in healthy young black and white men. J Natl Cancer Inst 76:45-48. 
90 
68. Foxman B, Klemstine KL, Brown PD. 2003. Acute pyelonephritis in US hospitals in 
1997: hospitalization and in-hospital mortality. Ann Epidemiol 13:144-50. 
69. Efstathiou SP, Pefanis AV, Tsioulos DI, et al. 2003. Acute pyelonephritis in adults: 
prediction of mortality and failure of treatment. Arch Intern Med 163:1206-1212. 
70. Nicolle LE, Friesen D, Harding GK, Roos LL. 1996. Hospitalization for acute 
pyelonephritis in Manitoba, Canada, during the period from 1989 to 1992; impact of 
diabetes, pregnancy, and aboriginal origin. Clin Infect Dis 22:1051-6. 
71. Ki M, Park T, Choi B, Foxman B. 2004. The epidemiology of acute pyelonephritis in 
South Korea, 1997–1999. Am J Epidemiol 160:985-993. 
72. Ismaili K, Lolin K, Damry N, Alexander M, Lepage P, Hall M. 2011. Febrile urinary 
tract infections in 0- to 3-month-old infants: a prospective follow-up study. J Pediatr 
158:91-4. 
73. Park S, Han JY, Kim KS. 2011. Risk factors for recurrent urinary tract infection in 
infants with vesicoureteral reflux during prophylactic treatment: effect of delayed 
contrast passage on voiding cystourethrogram. Urology 78:170-3. 
74. Wong SN, Tse NK, Lee KP, Yuen SF, Leung LC, Pau BC, Chan WK, Lee KW, Cheung 
HM, Chim S, Yip CM. 2010. Evaluating different imaging strategies in children after 
first febrile urinary tract infection. Pediatr Nephrol 25:2083-91. 
75. Winberg J, Andersen HJ, Bergstrom T, Jacobsson B, Larson H, Lincoln K. 1974. 
Epidemiology of symptomatic urinary tract infection in childhood. Acta Paediatr Scand 
Suppl:1-20. 
76. Wettergren B, Jodal U, Jonasson G. 1985. Epidemiology of bacteriuria during the first 
year of life. Acta Paediatr Scand 74:925-33. 
91 
77. Ginsburg CM, McCracken GH, Jr. 1982. Urinary tract infections in young infants. 
Pediatrics 69:409-12. 
78. Kanellopoulos TA, Salakos C, Spiliopoulou I, Ellina A, Nikolakopoulou NM, 
Papanastasiou DA. 2006. First urinary tract infection in neonates, infants and young 
children: a comparative study. Pediatr Nephrol 21:1131-1137. 
79. Bonadio W, Maida G. 2014. Urinary tract infection in outpatient febrile infants younger 
than 30 days of age: a 10-year evaluation. Pediatr Infect Dis J 33:342-4. 
80. Brkic S, Mustafic S, Nuhbegovic S, Ljuca F, Gavran L. 2010. Clinical and epidemiology 
characteristics of urinary tract infections in childhood. Med Arh 64:135-8. 
81. Corbier P, Dehennin L, Castanier M, Mebazaa A, Edwards DA, Roffi J. 1990. Sex 
differences in serum luteinizing hormone and testosterone in the human neonate during 
the first few hours after birth. J Clin Endocrinol Metab 71:1344-8. 
82. de Zegher F, Devlieger H, Veldhuis JD. 1992. Pulsatile and sexually dimorphic secretion 
of luteinizing hormone in the human infant on the day of birth. Pediatr Res 32:605-7. 
83. Andersson AM, Toppari J, Haavisto AM, Petersen JH, Simell T, Simell O, Skakkebaek 
NE. 1998. Longitudinal reproductive hormone profiles in infants: peak of inhibin B levels 
in infant boys exceeds levels in adult men. J Clin Endocrinol Metab 83:675-81. 
84. Lamminmaki A, Hines M, Kuiri-Hanninen T, Kilpelainen L, Dunkel L, Sankilampi U. 
2012. Testosterone measured in infancy predicts subsequent sex-typed behavior in boys 
and in girls. Horm Behav 61:611-6. 
85. Pediatrics AAo. 2011. Urinary tract infection: clinical practice guideline for the diagnosis 
and management of the initial UTI in febrile infants and children 2 to 24 months. 
Pediatrics 128:595-610. 
92 
86. Risma KA, Clay CM, Nett TM, Wagner T, Yun J, Nilson JH. 1995. Targeted 
overexpression of luteinizing hormone in transgenic mice leads to infertility, polycystic 
ovaries, and ovarian tumors. Proc Natl Acad Sci U S A 92:1322-1326. 
87. Risma KA, Hirshfield AN, Nilson JH. 1997. Elevated luteinizing hormone in prepubertal 
transgenic mice causes hyperandrogenemia, precocious puberty, and substantial ovarian 
pathology. Endocrinology 138:3540-7. 
88. Rulli SB, Ahtiainen P, Makela S, Toppari J, Poutanen M, Huhtaniemi I. 2003. Elevated 
steroidogenesis, defective reproductive organs, and infertility in transgenic male mice 
overexpressing human chorionic gonadotropin. Endocrinology 144:4980-90. 
89. Matzuk MM, DeMayo FJ, Hadsell LA, Kumar TR. 2003. Overexpression of human 
chorionic gonadotropin causes multiple reproductive defects in transgenic mice. Biol 
Reprod 69:338-46. 
90. Elkholi DGE, Nagy HM. 2016. The endocrine-metabolic disorders and adverse 
pregnancy outcomes in metabolically obese normal weight women with polycystic ovary 
syndrome. Womens Health Gynecol 2: 031. 
91. Agrawal R, Chimusoro K, Payne N, van der Spuy Z, Jacobs HS. 1997. Severe ovarian 
hyperstimulation syndrome: serum and ascitic fluid concentrations of vascular 
endothelial growth factor. Curr Opin Obstet Gynecol 9:141-4. 
92. Wang YC, Su HY, Liu JY, Chang FW, Chen CH. 2005. Maternal and female fetal 





Chapter 3. Population Dynamics During Formation of Kidney 
Bacterial Communities by Uropathogenic Escherichia coli 
Modified from McLellan LK, Daugherty AL, Hunstad DA. Population dynamics during 
formation of kidney bacterial communities by uropathogenic Escherichia coli. Submitted. 
 
Lisa K. McLellan1, Allyssa L. Daugherty1, and David A. Hunstad1,2* 
 
Departments of 1Pediatrics and 2Molecular Microbiology, Washington University School of 
Medicine, St. Louis, MO 
 
* Correspondence.  dhunstad@wustl.edu (D. A. Hunstad). 
 
Abstract 
Uropathogenic Escherichia coli (UPEC), the primary etiologic agent of urinary tract 
infections (UTIs), encounters a restrictive population bottleneck within the female mammalian 
bladder. Its genetic diversity is restricted during establishment of cystitis because successful UPEC 
must invade superficial bladder epithelial cells prior to forming clonal intracellular bacterial 
communities (IBCs). Here, we aimed to understand UPEC population dynamics during ascending 
pyelonephritis, namely formation of kidney bacterial communities (KBCs) in the renal tubular 
lumen and nucleation of renal abscesses. We inoculated the bladders of both male and female 
C3H/HeN mice, a background which features vesicoureteral reflux; we have previously shown 
that in this model, males develop severe, high-titer pyelonephritis and renal abscesses much more 
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frequently than females. Mice were infected with 40 isogenic, PCR-tagged (“barcoded”) UPEC 
strains, and tags remaining in bladder and kidneys were ascertained at intervals following 
infection. In contrast to females, males maintained a majority of strains within both the bladder 
and kidneys throughout the course of infection, indicating only a modest host-imposed bottleneck 
on overall population diversity during successful renal infection. Moreover, the diverse population 
in the infected male kidneys obscured any restrictive bottleneck in the male bladder. Finally, using 
RNA-in situ hybridization following mixed infections with isogenic UPEC bearing distinct 
markers, we found that despite their extracellular location (in the urinary space), KBCs are clonal 
in origin. This finding indicates that even with bulk reflux of infected bladder urine into the renal 
pelvis, successful ascension of UPEC to establish the tubular niche is an uncommon event.    
 
Introduction 
Within the unique environments of the mammalian host, expansion of a few bacteria into 
a large multicellular community is a complex process in which the bacteria must adapt to local 
conditions and survive mechanical, immunologic, and other stresses. These host forces may 
impose narrow bottlenecks in which the founding population undergoes a dramatic reduction in 
genetic diversity as it circumvents some facet of the host environment. Conversely, in the absence 
of such a bottleneck, the infecting population retains more genetic diversity, potentially allowing 
for more biological and phenotypic diversity (e.g., virulence and community behaviors) during 
infection. 
Uropathogenic Escherichia coli (UPEC), the primary etiologic agent of urinary tract 
infections (UTIs), encounters such a restrictive population bottleneck as it establishes clonal, 
biofilm-like intracellular bacterial communities (IBCs) within the superficial epithelial cells (facet 
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cells) of the bladder (1-6). During this pathogenic process, UPEC first bind these facet cells, and 
a subset of bacteria are then internalized. Within an infected facet cell, a single founder bacterium 
must avoid expulsion by the cell (7-9) and subsequently replicate in the cytoplasm, ultimately 
giving rise to a clonal IBC (1-3, 10). Indeed, a UPEC inoculum of 107 colony-forming units (CFU) 
during experimental cystitis in C3H/HeN and C57BL/6 female mice results in the formation of on 
average ~40-100 IBCs (1, 10-14). Bacteria within the IBC are protected from host defenses and 
antibiotic treatment, while those remaining in the bladder lumen are susceptible to neutrophil 
attack and to elimination via micturition (15-18). Bacteria within IBCs later re-emerge to infect 
naïve cells, initiating subsequent rounds of IBC formation (15, 19, 20). Thus, the infecting 
population becomes dominated by founder clones that successfully completed the IBC cycle (1, 
10, 19).  
Bacteria in the bladder lumen may also ascend the ureters to establish infection in the 
kidneys (pyelonephritis). Colonization of the kidney represents another event in which a 
population bottleneck might occur. While cystitis is clinically quite common (annual incidence of 
community-acquired cystitis is 3-13% in females and 0.5-3% in males), only ~1% of cystitis cases 
progress to pyelonephritis, which carries risks for hospitalization, sepsis, and renal abscess 
formation (21). In fact, 10-30% of pyelonephritis cases result in hospital admission, conferring $2-
4 billion in medical costs in the US annually (21). A common risk factor (primarily in childhood) 
for developing pyelonephritis is vesicoureteral reflux (VUR), identified in 30-45% of young 
children who present with febrile UTI (22-25). Pyelonephritis in children increases risk for renal 
scarring and associated lifelong morbidities such as hypertension and end-stage renal disease (24, 
26, 27), making it important to understand the pathophysiology and dynamics of upper-tract UTI.  
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The mouse is a highly suitable model for the study of UTI; however, preclinical modeling 
of UTIs has been performed almost exclusively in female mice, which in most backgrounds resolve 
upper-tract UTI without antibiotic treatment (28, 29). As a result, our molecular understanding of 
UPEC pathogenesis arises mostly from studies of the female bladder, while mechanisms of UPEC 
colonization of the kidneys remain a fertile area of study. More recently, we and others have 
developed models by which male mice can also undergo bladder inoculation (12, 30). Over a time 
course after equivalent bladder inoculation, males harbor significantly higher bladder and kidney 
bacterial loads than do females. Indeed, male C3H/HeN mice (a background with documented 
VUR (31-34)) uniformly develop severe pyelonephritis and >90% exhibit renal abscesses; these 
outcomes are observed in >70% of androgenized females (12, 35, 36) but only rarely in naïve 
females. As renal abscesses are being nucleated, tubules are occupied by biofilm-like collections 
of UPEC, which we termed kidney bacterial communities (KBCs) (35, 37). These intratubular 
(luminal) UPEC colonies are first visible microscopically 5 days post infection (dpi); thereafter, 
UPEC multiply rapidly and attract a robust neutrophil response, yielding fully formed KBCs 
within early abscesses by 7 dpi (35).  
Here, we employed this murine model and a set of “barcoded” UPEC isolates to interrogate 
the population dynamics of renal tubular colonization by UPEC. We found that in contrast to the 
female bladder, which imposes a marked bottleneck related to the requirement for intracellular 
invasion by UPEC, UTI in male mice features much less stringent restriction of genetic diversity 
among the infecting population, as measured in both the kidneys and bladder. Despite this overall 
diversity, we found that individual KBCs each were clonal, as revealed by in situ hybridization 
after mixed infection with distinctly tagged UPEC strains. These data indicate that while ascension 
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to the kidney does not constrain the bacterial population as a whole, pyelonephritis is initiated by 
individual bacteria that successfully colonize a group of contiguous nephron segments. 
 
Materials and Methods 
Bacterial strains and growth 
UPEC strain UTI89 was isolated from a patient with cystitis (10). UTI89 HK::KanR, 
UTI89 HK:ChlR, as well as a set of 40 isogenic, “barcoded” strains of UTI89 with PCR-
detectable tags, were previously published (1). This strain set was generated using the λ Red 
recombinase system (38). Individual strains were grown statically at 37 °C for 18 h in Luria-
Bertani (LB) broth, then combined in equal mixture based on optical density (OD600). Bacteria 
were pelleted at 7,500 × g at 4 °C for 10 min, then resuspended to an OD600 of 1.0 (~4 × 108 
CFU/mL) in sterile phosphate-buffered saline (PBS) for inoculation into mice. Type 1 pili 




All animal protocols received prior approval from the Institutional Animal Care and Use 
Committee at Washington University. Male C3H/HeN mice (Envigo) aged 8-9 weeks were 
infected as previously described (12). Briefly, mice were anesthetized with inhaled 3% 
isoflurane, and the lower abdomen was shaved and sterilized with 2% chlorhexidine solution. A 
3-mm midline abdominal incision was made through the skin and peritoneum, exposing the 
bladder. The bladder was aseptically emptied before 50 µl of inoculum (1-2 × 107 CFU in PBS) 
was injected into the bladder lumen via 30-gauge needle over 10 s. The bladder was allowed to 
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expand for an additional 10 s before the needle was removed. The peritoneum and skin incisions 
were closed with simple, interrupted sutures. At the time of surgery, mice were given sustained-
release buprenorphine (1 mg/kg SQ) for analgesia. At the indicated time points, mice were 
euthanized by CO2 asphyxiation. Bladders and kidney pairs were sterilely removed and 
homogenized in 1 mL or 0.8 mL PBS, respectively. Homogenates were serially diluted and 
plated on LB agar for CFU enumeration or fixed for histology. 
 
Detection of “barcoded” UTI89 strains 
Methods of detecting the “barcoded” UTI89 strains have been described previously (1). 
Briefly, 100 µL of each organ homogenate was spread onto LB agar and incubated overnight at 
37 °C. To collect genomic DNA, 2 mL of sterile water was added to bacterial lawns and scraped 
using bent, sterile glass pipettes. Genomic DNA was extracted via the Wizard genomic DNA 
purification kit; concentration was assayed by NanoDrop, and samples were diluted to 100 
ng/µL. 
Multiplex PCR was performed using 50 ng of genomic DNA, 1× Taq buffer (Invitrogen), 
2.5 mM MgCl2, 0.2 mM dNTP, 100 pmol each of primers BP-8C (cgtgccgatcaacgtctcattttcg) and 
BP-8K (gcttcaaaagcgctctgaagttcctatac), 2.5 U Taq DNA polymerase (Invitrogen), and a set of 3 
BP-xxF primers at final concentrations of ∼66.6 pmol/primer. BP-xxF primer sets are shown in 
Table 1. 
PCR reactions were cycled as follows: (1) initial denaturation of 94 °C for 3 min, (2) 10 
cycles of 94 °C for 30 s, 62 °C for 30 s with a 1 °C decrease per cycle, and 72 °C for 30 s, (3) 30 
cycles of 94 °C for 15 s, 55 °C for 15 s, and 72 °C for 30 s, and (4) a final 7-min extension at 72 
°C. The reaction products were run on 2.5% Tris-borate-EDTA (TBE) agarose gels. The 
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presence or absence of a band representing each individual strain in the multiplex PCR was 
determined by eye, by a scientist blinded to sample identity. Thirty-seven of the 40 tags were 
routinely detected in the inoculum. Three tags were statistically underrepresented in PCR of the 
inoculum pool and therefore were excluded from all analyses. Ambiguous bands were 
adjudicated by analysis in an independent multiplex PCR replicate.  
 
Histology and RNA in situ hybridization 
Infected bladders and kidneys were bisected and fixed in 10% neutral buffered formalin 
for 24 h. Fixed tissues were embedded in paraffin, sectioned, and processed for RNA in situ 
hybridization (RNA ISH) using Advanced Cell Diagnostics protocols and reagents. Slides were 
probed with RNAscope probes B-KanR (Catalog # 812371) and B-E.coli-CAT-C2 (Catalog # 
879281-C2). Detection was then performed using the RNAscope Multiplex Fluorescent Reagent 
Kit v2 (ACD document # 323100-USM). Images were acquired on an Olympus FV1200 




Statistical analysis was performed using Prism (GraphPad Software Inc., La Jolla, CA). 
Differences were analyzed with the unpaired, two-tailed, nonparametric Mann-Whitney U test. P 
values <0.05 were deemed significant. Quantitative Venn diagrams were created using the Eulerr 





Temporal course of male C3H/HeN kidney bacterial loads.  First, we temporally detailed the 
development of severe pyelonephritis in male C3H/HeN mice, infecting them with UPEC strain 
UTI89 and measuring organ bacterial loads at different time points post infection. Bladder 
bacterial loads were high immediately following inoculation (5 min post infection [mpi]; 
geometric mean 7.5 × 106 CFU/bladder) and remained consistent throughout 14 days post 
infection (dpi; Figure 1A). In contrast, initial kidney titers were substantially lower than bladder 
titers, with a geometric mean of 3.9 × 104 CFU/kidney pair 5 mpi (Figure 1B). Kidney titers 
significantly increased 3 dpi and then decreased modestly (but significantly) to ~106 CFU/kidney 
pair 7 and 14 dpi (Figure 1B). On the basis of this pattern, we reasoned that if a bottleneck were 
present during kidney infection in this model, it was occurring between 3 and 7 dpi (in contrast 
to the female mouse bladder, in which a marked bottleneck is observed 24 hpi (1)).  
The outcomes of experimental pyelonephritis in this model are substantially more severe 
in males than in females (12, 35). Here we observed that bacterial titers reaching the kidney 5 mpi 
were equivalent between male and female C3H/HeN mice (Figure 2). Therefore, initial ascension 
to the kidney (e.g., a sex difference in VUR) does not explain the sex differences we have observed 
in pyelonephritis severity.  
 
Establishment of ascending pyelonephritis in male C3H/HeN mice does not impose a 
narrow bottleneck at the population level.  In mice and in humans with properly functioning 
vesicoureteral junctions, retrograde flow of urine to the kidneys is precluded, thereby likely 
restricting the diversity of bacteria that can reach the kidney. In the absence of this anatomic 
protection (i.e., in C3H/HeN mice and humans with VUR (24, 39)), further bottlenecks might be 
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imposed during colonization of the collecting system and nephron. To investigate this, we 
infected male C3H/HeN mice with a set of 40 isogenic, PCR-barcoded isolates of UTI89 (1). 
Overall organ bacterial loads with this UTI89-derived strain set (Figure 3) matched our earlier 
data with the root strain (Figure 1). Using multiplex PCR, we assayed the proportion of isolates 
remaining at each time point, separately interrogating three niches (bladder, left kidney, and right 
kidney) to determine correlations among the tags detected in these locations. As expected, at 5 
mpi, all tags were detected in the bladder (Figure 4A), and most were detected in the kidneys 
(Figure 4B). Next we looked 1 dpi, when the bladder IBC cascade is occurring and in female 
mice a significant bladder bottleneck can be discerned (1, 2, 12, 15). In male C3H/HeN mice, a 
majority of isolates (bladder, 94%; kidneys, 97% and 94%) were detected 1 dpi (Figure 4). This 
sharply contrasted with published data in C3H/HeN females, in which 25% of tags remained in 
the bladder and 60% in the kidneys 1 dpi (1). At 7 dpi in male C3H mice, we observed a slight 
narrowing of diversity, with 70%, 74%, and 72% of tags remaining in the bladder and the left 
and right kidneys, respectively; these proportions were unchanged 14 dpi (Figure 4). This course 
aligns temporally with the modest reduction in total kidney bacterial load observed between 3 
and 7 dpi (Figure 1). Of note, no significant differences were seen between left and right kidneys 
at any time point (Figure 4).  
To confirm that the difference between our male data and published female data was not 
attributable to the mini-surgical inoculation method, we also infected a small cohort of female 
C3H/HeN mice using the same technique. Total organ bacterial loads in females were equivalent 
to those in males 5 mpi, but organ titers fell in females 7 and 14 dpi (Figure 5), consistent with 
prior data (12, 28). As was true in males (Figure 4), at 5 mpi in females 100% of tags were detected 
in the bladder (Figure 6), and most tags were detected in the left and right kidneys (Figure 6B,C). 
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At 7 dpi in females, a sharp bottleneck was observed in the bladder (48% of tags) and kidneys 
(23% and 20%, respectively); by 14 dpi this bottleneck was even more pronounced (bladder, 36% 
of tags; kidneys, 11% and 12%; Figure 6). These data are consonant with those previously reported 
in females infected via catheter (1).   
 
Shared distribution of bacterial clones among urinary tract niches is persistent in males. 
We next sought to understand whether the same isolates were found within all three niches, or if 
each niche was occupied by a unique set of UPEC clones. Using the multiplex PCR data from 
male C3H/HeN mice (Figure 4), we coded each strain and tracked them within each of the 
studied niches. The proportion of tags common to all three niches was 71%, 88%, 64%, and 58% 
of isolates at 5 mpi and 1, 7, and 14 dpi, respectively (Figure 7). The initial rise in shared 
proportion, followed by a slight narrowing, reflects a mild diversity bottleneck predicted by the 
overall bacterial loads in the male kidney (Figure 1) and recapitulates trends in the total number 
of tags across these time points (Figure 4).  
Meanwhile, a majority of isolates (78%) in female C3H/HeN mice occupied all three 
niches 5 mpi (Figure 8A), again indicating that initial ascension to the kidney does not impose a 
sex-discrepant population bottleneck (see also Figure 2). However, by 7 and 14 dpi in females, 
the proportion of isolates common to all three niches had fallen sharply (Figure 8B,C), in 
agreement with earlier work in females (1).  
 
Kidney bacterial communities (KBCs) arise from clonal expansion of founder bacteria 
within individual tubules.  Formation of IBCs in females imposes a bottleneck on bladder 
population diversity because only a small minority of bacteria successfully complete the IBC 
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cascade; each IBC in this model is formed from a single founder bacterium that has invaded a 
facet cell (1). While morphologic similarities exist between bladder IBCs and renal tubular 
KBCs, clonality in the IBC is a result of prerequisite intracellular invasion (1, 2, 15, 40). This is 
in contrast to KBCs which form in the extracellular space (tubular lumen) (35).  Therefore, we 
hypothesized that KBCs would be the product of multiple bacterial clones reaching the tubular 
lumen. To interrogate the clonal composition of KBCs, we infected C3H/HeN males with a 1:1 
mixture of UTI89 HK::KanR and UTI89 HK::ChlR (Figure 9). We determined the composition 
of the KBCs 2 wpi by RNA in situ hybridization (RNA ISH), detecting expression of KanR or 
ChlR. Of note, this method was chosen after standard immunofluorescence microscopy was 
judged to be inadequately specific for these markers and challenged by autofluorescence in the 
kidney. Surprisingly, visualized KBCs were always composed of either UTI89 HK::KanR or 
UTI89 HK::ChlR, but never both (of 87 KBCs visualized across 9 mice infected in four 
independent experiments), all were monochromatic; Figure 9). Within an individual kidney 
section, groups of KBCs formed from a single bacterial strain were located in spatially distinct 
areas of abscess (Figure 9). This finding indicates that at least in this preclinical model of 
ascending pyelonephritis, the KBC arises from growth and expansion of a founder bacterium that 
has ascended the nephron to establish a given intratubular focus of infection. 
 
Discussion 
We conclude that the more robust kidney infection observed in males reflects a greater 
number of successful founder bacteria (i.e., tagged strains) establishing renal colonization in the 
male host, despite initial inoculation that is equivalent between sexes. The kidney thus represents 
a niche, distinct from the bladder tissue, where successful clones can establish themselves and 
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replicate. These kidney-occupying UPEC clones, then, continuously descend from the kidney and 
contribute to ongoing pathogenesis in the bladder (and, if VUR is present, can likely exchange 
clones with the contralateral kidney). The harboring of a more genetically diverse infection in the 
kidneys in males – “upstream” of the bladder – thereby overcomes the population bottleneck that 
would otherwise be evident during initial colonization of the bladder. Meanwhile, the modest 
narrowing of genetic diversity in the male kidney between 3 and 7 dpi likely reflects a transition 
from bulk retrograde flow (into the renal pelvis with VUR) to molecular interactions that drive 
colonization of the nephron (35), potentially coupled with the arrival of phagocytes. In other 
words, arrival in the kidney in the setting of VUR does not impose a strict bottleneck on the 
bacterial population, while ascension into the nephron is a comparatively uncommon event 
accomplished by individual bacteria that express the requisite traits (e.g., for motility or 
attachment). This model predicts that KBCs are clonal in nature – a conclusion supported by our 
RNA ISH data. Of note, while IBCs in the bladder are clonal due to the process of UPEC 
internalization into facet cells, we have not observed an intracellular stage associated with KBC 
formation in our model (1, 35). 
This work furthers our understanding of UPEC population dynamics during UTIs, 
demonstrating that the susceptible kidney offers a distinct niche for success of bacterial clones 
and can overcome the bottleneck in genetic diversity that is imposed during cystitis. Future 
studies should aim to identify additional molecular determinants of host-pathogen interaction 
that permit establishment and persistence of upper-tract UTI. Specifically, the lack of sharp 
genetic restriction in the kidney may enable unbiased approaches (e.g., with transposon libraries) 
to discover such kidney-specific UPEC virulence factors. 
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Figure 1. Male C3H/HeN mice develop high-titer cystitis and pyelonephritis. Male 
C3H/HeN mice were infected with UTI89, and organs were harvested at the indicated intervals. 
(A) Bladder bacterial loads remained constant across the time points studied. (B) Kidney 
bacterial loads were statistically highest 3 dpi. Horizontal bars indicate geometric mean, and 
dotted line indicates limit of detection. *p<0.05, ***p<0.001.  
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Figure 2. Vesicoureteral reflux (VUR) is equivalent among male and female mice.  
C3H/HeN mice were infected with UTI89 by direct surgical inoculation of the bladder. There 
was no difference noted in bladder titers (A) or kidney titers (B) between males and females. 
Horizontal bars indicate geometric mean, and dotted line indicates limit of detection. Male data 
shown here are the same as those 5 mpi in Figure 1.   
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Figure 3. Male C3H/HeN bacterial loads with UTI89-derived set of “barcoded” isolates.  
Male C3H mice were infected with 40 PCR-tagged (“barcoded”) isogenic UPEC isolates. 
Bladder (A) and kidney (B) titers were enumerated at the indicated time points. Horizontal bars 




Figure 4. Male mice maintain a wide diversity of isolates in the bladder and kidneys.  We 
infected C3H/HeN male mice with 40 PCR-tagged (“barcoded”) isogenic UPEC isolates. 
Bacterial genomic DNA was extracted from bacterial outgrowths of organ homogenates. Tags 





Figure 5. Male and female C3H/HeN bacterial loads with UTI89-derived set of “barcoded” 
isolates.  Male (black circles) and female (blue triangles) C3H mice were infected with 40 PCR-
tagged (“barcoded”) isogenic UPEC isolates. Bladder (A), left kidney (B), and right kidney (C) 
titers were enumerated at the indicated time points. Horizontal bars indicate geometric mean, and 
dotted line indicates limit of detection. Male data displayed here are the same as in Figure 3, and 




Figure 6. In contrast to males, female C3H mice display a marked population bottleneck in 
the bladder and kidneys. We infected C3H/HeN male and female mice with 40 PCR-tagged 
(“barcoded”) isogenic UPEC isolates. Bacterial genomic DNA was extracted from bacterial 
outgrowths of organ homogenates. Tags remaining in the bladder (A), left kidney (B), and right 
kidney (C) of males (black circles) and females (blue triangles) were detected by multiplex PCR. 
Male data displayed here are the same as in Figure 4; statistical comparisons among male 
groups are omitted here for clarity. *p<0.05, ***p<0.001.  
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Figure 7. Niche distribution of UPEC in infected male C3H/HeN mice.  Using the multiplex 
PCR data gathered from bladders and kidneys, we quantified the sharing of tags across niches at 
5 mpi (A; n=4), 1 dpi (B; n=5), 7 dpi (C; n=9), and 14 dpi (D; n=10). Venn diagrams represent 
the average proportion of tags detected in the indicated niches. Niche colors: yellow, bladder; hot 
pink, left kidney; blue, right kidney. Overlap colors: orange, bladder and left kidney; green, 
bladder and right kidney; purple, left and right kidneys; rose, all three niches. Labels indicate 
measured proportions in each niche, while colored regions approximate these proportions 




Figure 8. Niche distribution of UPEC in infected female C3H/HeN mice.  Using the 
multiplex PCR data gathered from bladders and kidneys, we quantified the sharing of tags across 
niches at 5 mpi (A; n=4), 7 dpi (B; n=5), and 14 dpi (C; n=4). Venn diagrams represent the 
average proportion of tags detected in the various niches. Niche colors: yellow, bladder; hot 
pink, left kidney; blue, right kidney. Overlap colors: orange, bladder and left kidney; green, 
bladder and right kidney; purple, left and right kidneys; rose, all three niches. Labels indicate 
measured proportions in each niche, while colored regions approximate these proportions 




Figure 9. KBCs arise from clonal expansion of individual bacteria.  (A) Experimental 
scheme for inoculation of C3H/HeN male mice with UTI89 HK::KanR, UTI89 HK::ChlR, or an 
equal mixture of both, followed by KBC examination 2 wpi via RNA ISH and confocal 
microscopy. As controls, mice infected only with UTI89 HK::KanR displayed staining only with 
the KanR probe (B, green), and mice infected only with ChlR displayed staining only with the 
ChlR probe (C, red), although both probes were applied to slides. (D-E) After mixed infection, 
KBCs displayed staining for either KanR or ChlR; no mixed KBCs were seen. Representative 
images selected from 87 analyzed KBCs across 4 independent experiments; scale bars, 10 µm. 
(F) Digitally tiled scans of entire slides after mixed infection revealed KanR and ChlR KBCs 
within spatially separate areas of abscess in the same kidney; representative image shown. 
Colored arrowheads indicate respectively stained KBCs; scale bar, 200 µm.   
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Tables 
Table 1. BP-xxF primer sets and sequences for detection of “barcoded” UTI89 strains 
Set Primer name Primer Sequence Set Primer name Primer sequence 
1 BP 1F gtaccgcgcttaaacgttcag 5 BP 13F cttgcggcgtattacgttcag 
1 BP 2F gtaccgcgcttaaatagcctg 5 BP 14F cttgcggcgtattatagcctg 
1 BP 3F gtaccgcgcttaaaagtctcg 5 BP 15F cttgcggcgtattaagtctcg 
2 BP 4F gtaccgcgcttaataacgtgg 6 BP 16F cttgcggcgtatttaacgtgg 
2 BP 5F gtaccgcgcttaaactggtag 6 BP 17F cttgcggcgtattactggtag 
2 BP 6F gtaccgcgcttaagcatgttg 6 BP 18F cttgcggcgtattgcatgttg 
3 BP 7F gtaccgcgcttaatgtaaccg 7 BP 19F cttgcggcgtatttgtaaccg 
3 BP 8F gtaccgcgcttaaaatctcgg 7 BP 20F cttgcggcgtattaatctcgg 
3 BP 9F gtaccgcgcttaataggcaag 7 BP 21F cttgcggcgtatttaggcaag 
4 BP 10F gtaccgcgcttaacaatcgtg 8 BP 22F cttgcggcgtattcaatcgtg 
4 BP 11F gtaccgcgcttaatcaagacg 8 BP 23F cttgcggcgtatttcaagacg 
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Type 1 pili have long been considered the major virulence factor enabling colonization of 
the urinary bladder by uropathogenic Escherichia coli (UPEC). The molecular pathogenesis of 
pyelonephritis is less well characterized, due to previous limitations in preclinical modeling of 
kidney infection. Here, we demonstrate in a recently developed mouse model that beyond 
bladder infection, type 1 pili also are critical for establishment of ascending pyelonephritis. 
Bacterial mutants lacking the type 1 pilus adhesin (FimH) were unable to establish kidney 
infection in male C3H/HeN mice. We developed an in vitro model of FimH-dependent UPEC 
binding to renal collecting duct cells, and performed a CRISPR screen in these cells identifying 
desmoglein-2 as a primary renal epithelial receptor for FimH. The mannosylated extracellular 
domain of human DSG2 bound directly to the lectin domain of FimH in vitro, and introduction 
of a mutation in the FimH mannose-binding pocket abolished binding to DSG2. In infected 
C3H/HeN mice, type 1-piliated UPEC and Dsg2 were co-localized within collecting ducts, and 
administration of mannoside FIM1033, a potent small-molecule inhibitor of FimH, significantly 
attenuated bacterial loads in pyelonephritis. Our results broaden the biological importance of 
FimH, specify the first renal FimH receptor, and indicate that FimH-targeted therapeutics will 
also have application in pyelonephritis. 
 
Introduction 
Bacterial adhesion to urinary tract epithelium is a critical step in establishing urinary tract 
infection (UTI). Strains of uropathogenic Escherichia coli (UPEC), the main causative agents of 
UTIs, carry in their genomes a variable repertoire of adhesive pili assembled via the canonical 
chaperone-usher pathway (CUP) (1, 2). Given their importance in host-pathogen interactions, 
123 
UPEC adhesins including CUP pili have received considerable attention as mediators of 
pathogenesis and potential therapeutic targets (2-5). Within the mammalian bladder, UPEC 
employ type 1 pili tipped with the FimH adhesin, which binds α-D-mannose with stereochemical 
specificity. FimH-mediated UPEC binding to mannosylated uroplakins that coat the luminal 
surfaces of superficial uroepithelial (facet) cells is a key event in the pathogenesis of cystitis (6-
11). UPEC can subsequently be internalized into facet cells, where they replicate and establish 
intracellular bacterial communities (IBCs) (12-16). Bacteria within IBCs are protected from 
phagocytosis and other host defenses, and this community behavior within the bladder is a 
critical component of UPEC cystitis (17, 18).  
Less is known about the host-pathogen interactions enabling establishment of upper-tract 
UTIs, including pyelonephritis and renal abscess. Another CUP pilus, the P pilus, is tipped with 
the PapG adhesin, which has been implicated in human pyelonephritis (2, 19-21). However, its 
species-specific glycolipid receptor is absent in many animal models, including mice (22). 
Preclinical modeling of UTIs has been performed predominantly in female mice, and in a 
majority of murine backgrounds, upper-tract UTI resolves spontaneously and without significant 
sequelae (23, 24). Historically, female mice have been utilized as an experimental UTI model, 
which is typically initiated by catheter-directed inoculation of the mouse bladder, and reliable 
catheter access to the male mouse bladder is technically challenging (25-28). We previously 
developed an inoculation technique for initiating UTI in both male and female mice; when 
normal anatomic protections in males were thus bypassed, males evidenced more severe UTI, 
reflected throughout the course of infection by higher bladder and kidney bacterial loads, 
leukocytic infiltration, and inflammation (29). Of note, these findings aligned with human 
epidemiologic data showing higher morbidity from complicated UTI in men, and higher UTI 
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incidence in women with polycystic ovary syndrome (a common hyperandrogenic state) (30-36). 
In C3H/HeN mice (a background inherently featuring vesicoureteral reflux, a primary risk factor 
for upper-tract UTI in humans), males and androgen-exposed females developed severe 
pyelonephritis and renal abscesses (29, 37). Renal infection was nucleated by collections of 
UPEC occupying collecting ducts and more proximal segments of the nephron, which we termed 
kidney bacterial communities (KBCs) (37).  
The consistent development of severe pyelonephritis in this model enables detailed 
investigation of bacterial and host factors involved in the establishment of ascending upper-tract 
UTI. We identified a previously unappreciated role in the kidney for the mannose-binding 
adhesin FimH, which tips type 1 pili and is known to represent a major urovirulence factor 
within the bladder. High-affinity mannosides, which neutralize FimH function and are in 
development for the treatment of cystitis (4, 5, 38, 39), here significantly lowered bacterial 
burdens in the kidneys of mice with established pyelonephritis. To specify host factors required 
for upper-tract UTI, we performed a CRISPR/Cas9 screen in immortalized murine renal 
epithelial cells and identified desmoglein-2 (Dsg2) as a candidate receptor for FimH. The lectin 
domain of FimH (but not FimH with a point mutation that abolishes mannose binding) directly 
bound to the extracellular domain of human desmoglein-2 (DSG2). Finally, we observed co-
localization of UPEC with Dsg2 in the collecting ducts of mice with ascending pyelonephritis. 
Our studies demonstrate that disruption of FimH binding to renal tubular epithelium represents a 





Materials and Methods 
Bacterial strains and growth 
For mouse infections and for binding studies with IMCD-3 cells, bacteria were grown 
statically at 37 °C for 18 h in Luria-Bertani (LB) broth. For the CRISPR screen, type 1 pili were 
induced by static growth at 37 °C for 18 h, then 1:100 subculture and static growth for an 
additional 18 h. Bacterial strains were all previously published, with mutations generated using 
the λ Red Recombinase system (40) (see Table 1). Bacteria were pelleted at 7,500 × g at 4 °C for 
10 min, then resuspended to an OD600 of 1.0 (~4 × 108 colony-forming units [CFU]/mL) in 
sterile phosphate-buffered saline (PBS) for mouse infections, or in DMEM F-12 (Invitrogen 
1132-0033) supplemented with 10% fetal bovine serum (FBS; VWR 97068-085) for tissue 
culture experiments.  
 
Mouse infections 
All animal protocols complied with relevant ethical regulations and received prior 
approval from the Institutional Animal Care and Use Committee at Washington University 
(approval number 20180159). Male C3H/HeN mice (Envigo) aged 8-9 weeks were infected as 
previously described (29). Briefly, mice were anesthetized with inhaled 3% isoflurane, and the 
lower abdomen was shaved and sterilized with 2% chlorhexidine solution. A 3-mm midline 
abdominal incision was made through the skin and peritoneum, exposing the bladder. The 
bladder was aseptically emptied before 50 µl of inoculum (1-2 × 107 CFU in PBS) was injected 
into the bladder lumen via 30-gauge needle over 10 s. The bladder was allowed to expand for an 
additional 10 s before the needle was removed. The peritoneum and skin incisions were closed 
with simple, interrupted sutures. At the time of surgery, mice were given sustained-release 
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buprenorphine (1 mg/kg SQ) for analgesia. At the indicated time points, mice were euthanized 
by CO2 asphyxiation. Bladders and kidney pairs were sterilely removed and homogenized in 1 




Infected bladders and kidneys were bisected and fixed in 10% neutral buffered formalin 
for 24 h. Fixed tissues were embedded in paraffin, sectioned, and stained. Unstained slides were 
deparaffinized in xylenes, rehydrated in isopropanol, boiled in 10 mM sodium citrate, and 
blocked in 1% bovine serum albumin (BSA), 0.3% Triton-X 100 in PBS for 1-2 h at room 
temperature (RT). Tissue culture cells were fixed in methanol at -20 °C for 10 min and then 
blocked in 3% BSA for 1 h. Slides were incubated with primary antibodies for 4 h or overnight 
at RT and then (after washing in PBS) with secondary antibodies for 1 h at RT. Slides were then 
mounted with ProLong Gold antifade reagent (Invitrogen) and images acquired on an Olympus 
FV1200 confocal microscope. Primary antibodies utilized were: rabbit anti-type 1 pili (1:500 
dilution), rabbit anti-E. coli (1:1000 dilution, E3500-06C; US Biological), goat anti-E. coli 
(1:100-1:500 dilution, B65109G; Meridian Life Science), mouse anti-AQP2 conjugated with 
AlexaFluor 488 or 647 (1:50-1:200 dilution, sc-515770; Santa Cruz Biotechnology), mouse anti-
desmoglein 2 (1:100 dilution, 6D8, MCA2272T, BioRad), rabbit anti-desmoglein 2 (1:100, 
A303-758A, Bethyl Labs). Secondary antibodies utilized were AlexaFluor 488-conjugated goat 
anti-rabbit IgG (1:500 dilution, A11008; Life Technologies), AlexaFluor 647-conjugated chicken 
anti-rabbit IgG (1:200, A-21443;ThermoFisher), AlexaFluor 594-conjugated donkey anti-goat 
IgG (1:200, ab150132; abcam), Cy5-conjugated donkey anti-mouse IgG (1:250, 715-175-151; 
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JacksonImmuno), AlexaFluor 488-conjugated goat anti-rabbit IgG (1:1000, 111-095-144; 




Murine intramedullary collecting duct cells (IMCD-3; ATCC CRL-2123) were cultured 
in DMEM F-12 supplemented with 10% FBS. Medium included 0.1 mg/mL penicillin-
streptomycin (Gibco 15140-122) until the day before an experiment, when medium was changed 
to the above without antibiotics. Cells were maintained at 37 °C in a humidified atmosphere with 
5% CO2.  
 
In vitro binding assays  
The day before infection, IMCD-3 cells were seeded in 24-well plates. Medium was 
removed and cells were washed with PBS supplemented with Mg2+ and Ca2+ (PBS-MgCa; 
Sigma-Aldrich D8662). After inoculation with UPEC at a multiplicity of infection (MOI) of 20, 
plates were centrifuged at 400 × g for 3 min, then returned to the incubator. To enumerate bound 
CFU, after 45 min, wells were washed 5 times with PBS-MgCa, then lysed with 0.1% Triton X-
100 (Sigma T9284). To enumerate internalized CFU, after 60 min, cells were washed with PBS-
MgCa, treated with medium containing 50 µg/mL gentamicin (Thermo Fisher 15750060), and 
incubated at 37 °C for 90 min, then lysed with 0.1% Triton X-100. Lysates were serially diluted 
and plated to LB agar. Binding efficiencies were calculated in comparison to input wells, in 
which cells were inoculated with UPEC, incubated for 45 min, then lysed by addition of Triton 
X-100, and the well contents plated to LB agar for enumeration of input CFU.  
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Flow cytometry 
The day before infection, IMCD-3 cells were seeded in 6-well plates. Cells were infected 
with UPEC (at MOI 20-150) for 45 min, then washed as described above; cells were liberated 
with 0.05% trypsin-0.02% EDTA (Gibco), pelleted, and fixed in 4% paraformaldehyde (Electron 
Microscopy Sciences) for 30-60 min at RT. Cells were then blocked in 3% BSA for 1 h at RT. 
Cells were stained with primary rabbit anti-E. coli antibody (E3500-06C; US Biological) or 
isotype control (Rabbit serum; Sigma-Aldrich R9133) and secondary AlexaFluor 488-conjugated 
donkey anti-rabbit IgG (Invitrogen A21206) for 1 h each. Samples were stored in 3% BSA until 
analyzed on a Becton Dickinson (BD) LSR II Fortessa flow cytometer. Gating strategy is shown 
in Figure 1. 
 
Generation of virus and viral constructs 
Viruses were generated by transfecting 293T cells with lentiviral cDNA (VSV-G, 
pMD2.G, Addgene #12259; psPAX2, Addgene #12260; and construct of interest) using Opti-
MEM (Thermo Fisher 31985062) and TransIT LT1 transfection reagent (Mirus MIR2300). Virus 
was harvested 48 h post transfection. 
 
Library preparation and CRISPR screen 
IMCD-3 cells were transduced with lentivirus containing Cas9 (pXPR_101, Addgene 
#52962) by spinoculation (1 mL of Cas9 lentivirus onto 3 × 106 cells), then selected with 5 
µg/mL blasticidin (ThermoFisher A1113903). Cas9 activity was assayed by transducing cells 
with lentivirus containing pXPR_011 (Addgene #59702), which expresses eGFP and a sgRNA 
targeting eGFP, and selecting with 5 µg/mL puromycin (ThermoFisher A1113803). Loss of GFP 
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expression in cells expressing the eGFP guide was assessed by flow cytometry as described 
above. After Cas9 activity was confirmed, a Brie mouse sgRNA library (Brie pXPR_003, Batch 
3, Lot #m-AA89-20171107; generated by the Broad Institute) was transduced at MOI 0.5 into 
IMCD-3 Cas9 cells by spinoculation and selected with 5 µg/mL puromycin for 10 d until 
screening. 
For screening, 5 × 106 IMCD-3 cells were seeded into eighty 15-cm dishes the day before 
infection. Cells were infected with UTI89 at MOI 150 and incubated at 37 °C for 45-75 min, 
then fixed and stained for flow cytometry as described above. Samples were placed at 4 °C 
overnight on a tube roller; the following day, the 5% least FITC-positive cells were collected on 
a Sony iCyt Synergy BSC sorter. Tubes containing these low-FITC sorted cells were centrifuged, 
resuspended in 250 µl PBS, and stored at -20 °C. A total of 6 × 108 mock-treated cells were 
harvested, separated into aliquots of 8 × 107 cells, resuspended in 2 mL PBS, and stored at -20 
°C until genomic DNA preparation. DNA was extracted using QIAamp DNA Blood Maxi kit 
(Qiagen 51192) for mock samples and QIAamp DNA FFPE Tissue kit (Qiagen 56404) for 
experimental samples. 
 
Sequencing and bioinformatics 
Illumina sequencing was performed as described previously (41). Briefly, genomic DNA 
was aliquoted into multiple wells of a 96-well plate (up to 10 µg of DNA in 50 µL total volume). 
Samples were sequenced on an Illumina HiSeq 2000. Barcodes in the P7 primer were 
deconvoluted, and the sgRNA sequence was mapped to a reference file of sgRNAs in the Brie 
library. To normalize for different numbers of reads per condition, read counts per sgRNA were 
normalized to 107 total reads per sample; this normalized value was then log2 transformed. We 
130 
used the hypergeometric distribution method to rank sgRNAs and calculate gene p-values using 
the probability mass function of a hypergeometric distribution 
(https://portals.broadinstitute.org/gpp/public/analysis-tools/crispr-gene-scoring-help). We 
considered candidate genes those having an average log fold change >0.5 and a false discovery 
rate >2.5 (41, 42). For input of the hypergeometric distribution ranking, we subtracted the log2 
normalized read values of the uninfected unsorted IMCD-3 Brie library from the log2 normalized 
read values of the 5% lowest UPEC-bound sorted cells. We used R Studio to visualize the results 
of the hypergeometric distribution analysis. 
 
Generation of Dsg2 knock-down clones (C4 and F11) 
Dsg2 knock-down clones C4 and F11 were among hundreds generated by the Genome 
Engineering and iPSC Center at Washington University School of Medicine. IMCD-3 cells were 
nucleofected with Cas9 and a Dsg2-specific sgRNA (5’ GGAACTACGCATCAAAGTTCTGG 
3’). Single-cell clones were isolated by FACS and expanded in 96-well plates. Cells were 
harvested, and genomic DNA was amplified and subjected to targeted deep sequencing of a 
~400-bp amplicon flanking the gRNA target. Clones were screened for frameshifts by 
sequencing the target region with Illumina MiSeq at ~1500× coverage. We obtained no clones 
that completely lacked Dsg2 expression. Frameshift mutations identified in knock-down clones 







RNA was isolated from tissue culture cells using the Qiagen RNeasy kit. qPCR was 
performed using the Applied Biosystems TaqMan RNA-to-Ct 1-Step Kit (ThermoFisher 
4392938) and the probes listed in Table 3 (Integrated DNA Technologies).  
 
Immunoblot 
Samples were separated by SDS-PAGE and transferred to a polyvinylidene difluoride 
(PVDF) membrane (Millipore) using overnight wet transfer (48mM Tris pH 9.2, 38mM glycine, 
20% methanol, 0.05% SDS). After blocking for 6-8 h with 5% milk in PBS-T, blots were probed 
with rabbit anti-desmoglein-2 (1:250 dilution, A303-758A Bethyl Labs) and mouse anti-β-actin 
(1:100,000 dilution, 3700; Cell Signaling) in PBS-T with 5% milk overnight. Blots were then 
secondarily probed with HRP-conjugated sheep anti-mouse IgG (1:1000 dilution, NA931V; GE) 
and HRP-conjugated donkey anti-rabbit IgG (1:1000 dilution, NA934V; GE) for 1 h. Gels were 
developed using Clarity and Clarity Max Western ECL substrates (1705060 and 1705062; 
BioRad). Western blot images were analyzed with ImageJ. 
 
Protein production and biolayer interferometry (BLI) 
Methods for purification of full-length FimH and the lectin domain (FimHLD; amino acids 
1-160) have been described previously (10). Briefly, untagged FimHLD was purified from E. coli 
periplasmic extracts using ion-exchange and size-exclusion chromatography, dialyzed into sterile 
PBS, and stored at 4 °C until use.  
Expression constructs for 6×His-tagged human DSG2 EC1-5 (amino acids A1-A553) or 
DSG2 EC1-3 (amino acids A1-N332) (kind gifts of O. Harrison and L. Shapiro (43)) were 
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transfected (1 µg/mL of culture) into Expi293F cells (ThermoFisher) using Opti-MEM. Six days 
post transfection, the supernatant containing the 6×His-tagged DSG2 ectodomains was collected, 
dialyzed into 20mM Tris, 150mM NaCl pH 8 overnight at 4 °C,  batch purified by nickel-
nitrilotriacetic acid (Ni-NTA) affinity chromatography, and then further purified by HiLoad 
16/600 Superdex 200 size-exclusion chromatography (GE Healthcare). Protein was concentrated 
and was exchanged into a final buffer of sterile PBS, then stored at 4 °C until use in binding 
experiments. DSG2 EC1-5 was also expressed in Expi293F GnTI- cells (which generate proteins 
lacking complex N-linked glycans but decorated only with high mannose) and purified as 
described above. 
All BLI experiments were performed in 10 mM HEPES (pH 7.4), 150 mM NaCl, 1 mM 
CaCl2, 3 mM EDTA, and 0.005% P20 surfactant with 1% BSA at 25 °C using an Octet-Red96 
device (Pall ForteBio). DSG2 variants were biotinylated using EZ-Link NHS-PEG4-Biotin 
(Thermo Fisher) per manufacturer’s instructions. Biotinylated DSG2 was loaded onto streptavidin 
biosensors (ForteBio), then incubated with different concentrations of FimHLD or FimHQ133K (10 
µM to 156 nM) for 15 min followed by a 20 min dissociation. Real-time data were analyzed using 
BIAevaluation 3.1 (GE Healthcare), and kinetic curves were fitted using a global 1:1 binding 
algorithm with drifting baseline. 
 
Mannoside treatment 
Male C3H/HeN mice were infected as described above. Beginning 5 dpi, mice were 
given mannoside FIM1033 (gift of Fimbrion Therapeutics), 8 mg/kg in sterile PBS with 4% 
DMSO, by intraperitoneal injection every 8 h for 24 or 48 h. Mock-treated mice were injected 
with 4% DMSO in sterile PBS. Mice were sacrificed 6 h post last treatment dose. 
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Statistical analysis 
Statistical analysis was performed using Prism 8 (GraphPad Software). Differences were 
analyzed with the unpaired, two-tailed, nonparametric Mann-Whitney U test. P values <0.05 
were deemed significant. 
 
Results 
Type 1 pili are required for both bladder and kidney infection in male C3H/HeN mice.  
Type 1 pili have long been implicated in pathogenesis of UPEC cystitis, but only recently have 
new experimental models enabled interrogation of their role in pyelonephritis. We infected male 
C3H/HeN mice with either wild-type UTI89 (a prototypic UPEC strain), or UTI89∆fimH, an 
isogenic mutant lacking the type 1 pilus adhesin (16, 44). Two weeks post infection (wpi), 
UTI89∆fimH was sharply attenuated compared to wild-type in bladder and kidney bacterial loads 
(p<0.0001; Figure 2A) and in incidence of visible renal abscess (1/16 vs 13/13; p<0.0001). We 
confirmed that UTI89∆fimH reached the kidney normally following bladder inoculation, as 
kidney bacterial loads 24 hours post infection (hpi) were equivalent to wild-type (Figure 3). An 
analogous defect was confirmed using the urosepsis UPEC isolate CFT073, whose isogenic 
CFT073∆fimH mutant failed to colonize the kidney 2 wpi (Figure 4). Using 
immunofluorescence microscopy, we demonstrated type 1 pili expression by UPEC in KBCs 
located within abscesses 2 wpi (Figure 2B). As UTI89 carries ten full or partial CUP operons 
(45), we similarly tested deletion mutants in each of the annotated CUP pili. No other CUP pilus 
mutants exhibited a defect in bladder or kidney infection in male C3H mice 2 wpi, after 
inoculation either alone or in competition with wild-type UTI89 (Figure 5 and data not shown).  
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The pilin and lectin domains of FimH together exist in an equilibrium between tense and 
relaxed states with differential mannose binding affinity. Conversion between these states is 
governed in part by a catch-bond mechanism (9, 46-48). In the relaxed state, the FimH lectin 
domain samples conformational ensembles, allowing it to act as a molecular tether, with the 
mannose binding pocket in a conformation able to bind mannose tightly; in the tense state, the 
mannose pocket is open and thus binds mannose only weakly(8). In the bladder, the ability of 
FimH to transition between these states allows optimal epithelial binding by UPEC (8, 49, 50). 
We infected male C3H/HeN mice with wild-type UTI89 or with UTI89∆fimH complemented 
with FimHA27V/V163A, a variant that predominantly adopts the relaxed conformation (high 
mannose-binding state). Paradoxically, UPEC expressing this variant are attenuated during 
cystitis in female mice(8, 49, 50). Here, we found similarly that UTI89 FimHA27V/V163A also 
failed to establish pyelonephritis, with significantly lower bacterial loads in kidneys (p=0.001) as 
well as bladder (p<0.0001) compared to wild-type UTI89 (Figure 6A). Further, the type 1 pilus 
rod, formed from FimA subunits, normally can unwind from a tightly coiled helix to a more 
linearized rod; this action is hypothesized to help UPEC withstand the shear force of urine flow 
(51-53). A variant in the type 1 pilus helical rod, FimAA22R, requires less force to adopt the 
unwound form, but UPEC expressing this variant are attenuated in the female mouse bladder 
(54). We found that UTI89 expressing FimAA22R was also attenuated in the kidneys (p=0.0038) 
and bladders (p<0.0001) of male C3H/HeN mice 2 wpi (Figure 6B). Thus, the conformational 
dynamics of type 1 pili, critical in establishing bladder infection, are similarly important in 
ascending pyelonephritis. Collectively, our data demonstrate that beyond their well-described 
role in establishing bladder infection, UPEC type 1 pili are also important in initiating ascending 
pyelonephritis and renal abscess. 
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Murine collecting duct cells display type 1 pili-dependent UPEC binding.  The collecting 
duct is the first nephron segment encountered by ascending UPEC. Consistent with prior findings 
(55, 56), ascending UPEC were located within the collecting ducts in C3H/HeN mice 5 dpi 
(Figure 7A). Therefore, we chose mouse intramedullary collecting duct (IMCD-3) cells to 
establish an in vitro model of type 1 pili binding to kidney epithelium. In standard bacterial 
binding assays, UTI89 ∆fimH was significantly attenuated compared to wild-type UTI89 (Figure 
7B), recapitulating what we observed in in vivo infection. Following IMCD-3 cell infection and 
anti-E. coli antibody staining, we confirmed by flow cytometry the in vitro binding defect of 
∆fimH (Figure 7C,D). Furthermore, UPEC binding to collecting duct cells was significantly 
inhibited by methyl α-D-mannopyranoside and to an even greater extent by mannoside FIM1033 
(Figure 8). Thus, the in vivo requirement for type 1 pilus function is reflected in in vitro binding 
of UPEC to IMCD-3 cells.  
 
A CRISPR screen identifies candidate type 1 pilus receptor desmoglein-2. Although type 1 
pili are well known as critical virulence factors in the bladder (6-11), they have not been 
implicated in ascending pyelonephritis, and a cognate receptor has not been identified. To screen 
for host genes participating in type 1 pili-dependent binding of UPEC to collecting duct 
epithelium, we performed a genome-wide CRISPR-Cas9 screen using the Brie sgRNA library in 
IMCD-3 cells (Figure 9A), with 4× nominal coverage of each gene within the mouse genome 
(41). The pooled library of edited cells were inoculated with UPEC, fixed and stained, and 
subsequently flow-sorted for the population of cells with the lowest fluorescence (Figure 9A). 
Genomic DNA was extracted from sorted cells, subjected to Illumina sequencing, and analyzed 
using the probability mass function of a hypergeometric distribution to identify candidate genes 
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statistically associated with bacterial binding (Table 4) (41, 42). Among these candidates 
(Figure 9B), we focused on genes encoding proteins that would be localized to the cell surface 
and could be available to interact with bacterial pili (57, 58). The screen revealed deficient 
UPEC binding to cells edited with guides targeting desmoglein-2 (Dsg2; Figure 9B), which 
encodes a mannosylated cell junctional protein displayed on kidney tubular epithelia throughout 
the nephron (43, 57, 59). By fluorescence microscopy of IMCD-3 cells inoculated with UPEC, 
we observed co-localization of UPEC with Dsg2 (Figure 9C). 
 
FimH binds DSG2 in vitro.  Desmoglein-2 is a member of the cadherin superfamily and in 
humans and mice comprises five extracellular cadherin (EC) domains, a single transmembrane 
segment, and an intracellular domain (Figure 10A). To determine whether desmoglein-2 binds 
directly to FimH, we generated two forms of recombinant 6×His-tagged human DSG2 (EC1-5, 
amino acids A1-A553) (43) in wild-type Expi293F cells, as well as from Expi293F GnTI- cells 
(which lack complex N-glycans and instead exhibit uniform GlcNAc2Man5 glycosylation). We 
also purified the lectin domain of FimH (FimHLD, amino acids 1-160) from E. coli (Figure 11). 
By biolayer interferometry (BLI), FimHLD bound to DSG2 EC1-5 from wild-type cells with an 
apparent binding affinity of 1.6 µM (Figure 10B and Figure 12). In comparison, DSG2 EC1-5 
purified from GnTI- cells exhibited higher binding to FimHLD (KD,apparent = 484 nM, p=0.008; 
Figure 10B), consistent with preferential binding of FimHLD to highly mannosylated structures. 
In contrast, the FimHQ133K mutant, which lacks mannose binding activity (10), did not bind to 
either variant of DSG2 EC1-5 (p = 0.036; Figure 10B). Finally, FimHLD bound only minimally 
to DSG2 EC1-3 (amino acids A1-N332; p = 0.015 vs EC1-5; Figure 10B). Taken together, these 
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data show that FimH binds the extracellular portion of DSG2 in a mannose-dependent manner, 
and that DSG2 domains EC4 and/or EC5 mediate FimH binding.  
To validate Dsg2 as a UPEC receptor, we edited IMCD-3 cells with CRISPR-Cas9 to 
achieve specific deletion of Dsg2. Though hundreds of edited clones were screened, no clones 
entirely lacking Dsg2 expression were obtained, suggesting that complete Dsg2 deletion may be 
physiologically detrimental. Of note, germline Dsg2 deletion in mice is lethal (60). We did 
identify two gene-edited clones (namely C4 and F11) that exhibited sharply reduced Dsg2 
transcript expression (Figure 13A); by quantitative immunoblot of cell lysates, these knock-
down clones expressed significantly less Dsg2 protein than wild-type IMCD-3 cells (Figure 
13B; median C4/WT ratio 4.3%, p=0.0022; median F11/WT ratio 4.7%, p=0.0087). By flow 
cytometry, median binding of C4 and F11 cells by UPEC was decreased by 33% and 46% 
compared with WT IMCD-3 cells (p=0.0235 and 0.0032, respectively; Figure 13C,D).  
 
Targeting the Dsg2-FimH interaction during in vivo infection.In the kidneys of UPEC-
infected C3H/HeN mice, we identified UPEC within Dsg2+, aquaporin-2+ collecting ducts 5 dpi 
(Figure 14A). Across multiple sections from several infected mice, of 239 intratubular UPEC 
colonies visualized 5 dpi, 228 (95%) resided in Dsg2+ tubules.  
Finally, we hypothesized that if the Dsg2-FimH interaction was important for 
pyelonephritis, mannosides could be employed therapeutically in our mouse model. Male 
C3H/HeN mice were inoculated with UTI89, and early KBCs were allowed to form over 5 days 
(37, 61); mice were then treated with mannoside FIM1033 (formerly termed 29R(5)) (Figure 
14B). Compared with mock-treated mice, bladder and kidney bacterial loads were significantly 
reduced by mannoside treatment for 24 h (kidney p=0.0434, bladder p=0.0255; Figure 14C) and 
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even more so with treatment for 48 h (kidney p=0.0042, bladder p=0.0003; Figure 14D). These 
in vivo data support a model in which desmoglein-2 on collecting duct epithelium serves as a 
receptor for UPEC FimH during pyelonephritis in vivo.  
 
Discussion 
In this study, we reveal the importance of type 1 pili in host-pathogen interaction during 
ascending pyelonephritis and identify desmoglein-2 as the first candidate receptor for FimH on 
renal tubular epithelium. Our findings in male C3H mice confirm that type 1 pili are essential for 
cystitis (as in female mice (6-11)), but more importantly provide both in vitro and in vivo 
evidence of the function of FimH in bacterial infection of the kidney. Furthermore, our ability to 
mitigate kidney infection with mannosides suggests that type 1 pilus-directed therapeutics 
currently under development for recurrent cystitis (2, 4, 5, 38, 39) may also be useful in 
pyelonephritis.  
Compared to bacterial cystitis, significantly less is known about the pathogenesis of 
UPEC pyelonephritis, primarily due to the fact that female mice of most backgrounds resolve 
kidney infection spontaneously (23, 24). Work in humans has identified genetic factors that 
confer susceptibility to pyelonephritis and renal scarring, including polymorphisms reducing 
IRF3 or CXCR1 (encoding IL-8 receptor) expression, in certain UTI-prone kindreds (62-65). 
Previously, P pili have been considered the major adhesin in kidney infection (2, 19, 21). This 
work has been complicated by allelic variation in the P pilus adhesin PapG correlated with 
differing affinity for various glycolipid receptors that are differentially expressed in the kidneys 
of humans and model animals, including mice (2, 66). While P pili are enriched in the genomes 
of pyelonephritis-associated UPEC isolates for children with acute pyelonephritis, a significant 
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proportion of UPEC isolates from women with acute and recurrent UTI lack P pili, suggesting a 
role for other adhesin(s) during ascending infection (21, 67-69). 
Recent works have employed new mouse models (including C3H/HeOuJ mice, male 
C3H/HeN mice, and androgenized female mice) which now enable detailed study of the 
pathogenesis of kidney infection and abscess formation (29, 37, 55). In our model of ascending 
UTI, type 1 pili were shown to be essential for maintenance of renal infection, through both 
genetic mutation of the pilus and pharmacological inhibition with mannosides. Other work has 
hinted at a role for type 1 pili and mannose targets in kidney infection (70-73). For instance, 
signaling through C5a receptor 1 (C5aR1), which regulates inflammatory cell recruitment in 
UPEC infection, may also enhance presentation of mannosylated glycoproteins by primary renal 
tubular epithelial cells (71, 72). Meanwhile, experiments in which tubular infection was initiated 
via microinjection of UPEC directly into rat nephrons posited a role for type 1 pili in 
interbacterial interactions and biofilm formation (70). While our work indicates that FimH 
mediates renal epithelial binding (in agreement with prior staining of kidney sections using 
purified adhesins (21, 74)), the present work does not exclude a role for type 1 pili in 
interbacterial interactions and/or biofilm formation within the kidney. Inhibition of any of these 
interactions by administration of mannosides might exert therapeutic benefit in pyelonephritis. 
Using a CRISPR-Cas9 screen, we identified desmoglein-2 as a receptor for UPEC during 
ascending infection. DSG2 is a member of the cadherin family of Ca2+-binding proteins, 
involved in intercellular junctions via the desmosome (75, 76). Its identified roles in mammalian 
disease states are limited; of note, cardiomyocyte-specific conditional knockout of Dsg2 in mice 
phenocopies human arrhythmogenic cardiomyopathy, which is correlated with loss-of-function 
DSG2 mutations (77, 78). Interestingly, other members of the desmoglein family also act as 
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receptors for unrelated microbes (79). Dsg2 has been specifically implicated as a receptor for 
adenovirus serotypes 3, 7, 11, and 14 (80, 81); of note, serotype 11 is most commonly associated 
with hemorrhagic cystitis in renal and other transplant recipients (82). Along the length of the 
nephron, DSG2 expression is highest within the collecting duct and decreases as one ascends to 
more proximal segments of the tubule (59). As a family, desmogleins (and other cadherins) 
exhibit a unique form of mannosylation in which α-D-mannose (the binding target of type 1 pili) 
is present as a novel O-linked glycosylation modification (43). Prior studies have demonstrated 
FimH binding to N-linked glycans containing a terminal mannose (7, 10, 83, 84). While N-linked 
glycans are present on each EC domain of DSG2 (43), our data suggest that FimH interaction 
with native DSG2 is mediated through EC4 and/or EC5 (Figure 10). Of particular interest is the 
possibility that the cadherin-specific O-linked α-D-mannose on EC4 may represent the preferred 
binding target. While FimH canonically binds mannose, existing studies have not aimed to 
interrogate whether the spatial arrangement of nearby amino acid residues may also influence 
binding affinity.  Future work, including determination of the structural basis of DSG2-FimH 
binding, will further address this question.   
One limitation of this study is that we were unable to obtain a complete Dsg2 knockout 
cell line, indicating that complete absence of Dsg2 may confer a significant defect in in vitro 
growth of IMCD-3 cells. It is becoming better appreciated that CRISPR-generated knockout cell 
clones display phenotypic plasticity, and residual low-level protein expression often persists 
(85). Therefore, it is difficult to precisely quantify what proportion of UPEC binding is to Dsg2 
as opposed to other mannosylated cell-surface receptors. It is possible that Dsg2 knock-down 
leads to compensatory production of other proteins; that Dsg2 knock-down reveals the 
participation of more minor binding partners for type 1 pili; or that the amount of residual Dsg2 
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in the knock-down clones provides sufficient receptors for UPEC to bind a modest proportion of 
cells. The present data do not distinguish among these possibilities. 
Our results indicate that Dsg2 may not be the sole receptor for UPEC within the kidney, 
but rather the most important receptor among others on renal tubular epithelium. The apical 
surfaces of bladder epithelial facet cells are coated with a comparatively restricted set of 
proteins, largely four uroplakins (86). Among these, uroplakin Ia bearing N-linked oligomannose 
is thought to be the primary receptor important for UPEC binding of intact bladder epithelium 
(6-8, 10, 11, 87). In contrast, the renal tubular epithelium bears a wider variety of surface 
proteins, a number of which might be mannosylated. Of note, CRISPR knock-down of the 
glycosyltransferase Dad1 on IMCD-3 cells also conferred a UPEC binding defect (Figure 9B), 
suggesting that this enzyme may play a role in mannosylation of Dsg2 and/or other potential 
receptors for UPEC type 1 pili. Additionally, multiple innate immune genes were statistically 
enriched in the CRISPR screen (Figure 9B), hinting that innate response pathways may alter 
receptor expression and thereby influence UPEC binding; this too represents an avenue for future 
study. 
The present work highlights the importance of type 1 pili and the mannosylated epithelial 
receptor desmoglein-2 in UPEC colonization of renal tubules. As the type 1 pilus adhesin FimH 
is already targetable by small-molecule inhibitors and vaccines in patients with cystitis (3, 68, 
88), these therapeutics may prove useful in prevention or treatment of upper-tract UTI as well. 
Finally, desmoglein-2 is expressed widely across many epithelia, suggesting that it may serve as 
a FimH receptor in other UTI-relevant niches, perhaps as a secondary receptor in the urinary 
bladder or in the gut. 
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Figure 1. Gating strategy for flow cytometry experiments.  Samples were gated on single 
cells. Representative samples of IMCD-3 cells treated with media alone (red) and WT UTI89 
(blue) shown.  
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Figure 2. Type 1 pili are required for bladder and kidney infection.  (A) Male C3H/HeN 
mice were infected with UTI89 (closed circles) or UTI89∆fimH (open diamonds), and organs 
were harvested 2 wpi. Bacterial loads after WT infection were significantly higher than with 
∆fimH in both the bladder and kidneys (****p<0.0001). Horizontal bars indicate geometric 
mean, and dotted line indicates limit of detection. n=13-16 mice per group over 3 independent 
experiments. (B) Immunofluorescence microscopy of C3H/HeN male kidney 2 wpi with UTI89, 
showing expression of type 1 pili within kidney bacterial communities (magnified in inset; green, 
anti-type 1 pili; red, SYTO 61 nuclear stain). Scale bar, 20 μm.   
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Figure 3. UTI89∆fimH are present within the bladders and kidneys of male C3H/HeN mice 
24 hpi.  Male C3H/HeN mice were infected with UTI89 (closed circles) or UTI89∆fimH (open 
diamonds), and organs were harvested 24 hpi. No significant difference in bacterial loads 
between WT and ∆fimH were observed, indicating that ∆fimH reaches the kidney normally after 
inoculation of the bladder.  Horizontal bars indicate geometric mean, and dotted line indicates 
limit of detection. n = 9 mice per condition over 2 independent experiments.   
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Figure 4. Urosepsis isolate (CFT073) lacking FimH also displays fitness defect 2wpi.  Male 
C3H/HeN mice were infected with CFT073 (closed circles) or CFT073∆fimH (open diamonds), 
and organs were harvested (A) 24 hpi or (B) 2 wpi. No significant differences in bacterial loads 
were observed 24 hpi; ∆fimH was attenuated significantly 2 wpi in both the bladder (*p = 
0.0482) and kidneys (****p<0.0001).  Horizontal bars indicate geometric mean, and dotted line 
indicates limit of detection. (A) n=10 mice per condition over 2 independent experiments; (b) 
n=13-14 mice per condition over 3 independent experiments.  
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Figure 5. Knockouts of the other CUP pili in UTI89 do not cause a colonization defect.  
Male C3H/HeN mice were infected with UTI89 (closed circles) or isogenic, individual UTI89 
CUP pili mutants (open diamonds), and organs were harvested 2 wpi. None of these CUP pili 
mutants displayed defects in bladder or kidney colonization. Horizontal bars indicate geometric 





Figure 6. Functional variants of type 1 pili are ineffective in establishing kidney infection.  
Male C3H/HeN mice were infected with UTI89 (closed circles) compared to type 1 pili variants. 
Bladders and kidneys harvested 2 wpi yielded higher bacterial loads of wild-type (WT) UTI89 
compared to (A) UTI89 FimHA27V/V163A (open diamonds) (bladder ****p<0.0001, kidney 
***p=0.0001) or (B) UTI89 FimAA22R (open diamonds) (bladder ****p<0.0001, kidney 
***p=0.0038). Horizontal bars indicate geometric mean, and dotted line indicates limit of 
detection. (A) n=13-19 mice per condition over 3 independent experiments; (B) n=10-15 mice 
per condition over 2 independent experiments. 
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Figure 7. Murine collecting duct cells display type 1 pili-dependent UPEC binding.  (A) 
Early intratubular colonies of UPEC (green) were localized 5 dpi in male C3H/HeN mice 
collecting duct tubules (AQP2+, red; DAPI, blue; scale bar, 10 µm). (B) To intramedullary 
collecting duct (IMCD-3) cells, WT UTI89 (filled circles) displayed significantly higher levels 
of bacterial binding than ∆fimH (open diamonds; ****p<0.0001) (MOI 20). Horizontal bars 
indicate geometric mean. n= 12 samples per group over 4 independent experiments. (C, D) 
Binding of IMCD-3 cells by UTI89 or ∆fimH was quantified by flow cytometry after gating on 
single cells. (C) FITC signal (anti-E. coli) was evident in IMCD-3 cells infected with wild-type 
UTI89 (navy blue) compared with medium alone (green); infection with ∆fimH yielded no signal 
(orange). (D) Cells infected with UTI89 displayed significantly higher median fluorescence 
intensity (MFI) than those treated with medium alone or ∆fimH (****p<0.0001). n=8-15 samples 
per group over 6 independent experiments.  
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Figure 8. Methyl α-D-mannopyranoside and mannoside FIM1033 inhibit UPEC binding to 
collecting duct epithelial cells. (A) FITC signal (anti-E. coli) on IMCD-3 cells infected with 
wild-type UTI89 (navy blue) compared to infection with UTI89 ∆fimH (orange) or with wild-
type UTI89 in media containing 2% methyl α-D-mannopyranoside (teal). (B) Binding of IMCD-
3 cells by UTI89 (closed circles) or ∆fimH (open diamonds) after addition of methyl α-D-
mannopyranoside was quantified by flow cytometry after gating on single cells. Significance is 
shown in comparison to WT UTI89 without methyl α-D-mannopyranoside (**p<0.01, 
***p<0.001). n=6-9 samples per condition over 3 independent experiments. (C) FITC signal 
(anti-E. coli) on IMCD-3 cells infected with wild-type UTI89 (navy blue) compared to infection 
with UTI89 ∆fimH (orange) or with wild-type UTI89 in media containing FIM1033 (0.1µM, 
light pink; 1µM, dark pink; 10µM, maroon). (D) Binding of IMCD-3 cells by WT UTI89 (closed 
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circles) with or without addition of FIM1033, or by ∆fimH (open diamonds), was quantified by 
flow cytometry after gating on single cells. Horizontal bars indicate geometric mean, and 
significance is shown in comparison to WT UTI89 without FIM1033 (****p<0.0001). n=9 
samples per condition over 3 independent experiments.  
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Figure 9. A lentiviral CRISPR screen identifies candidate type 1 pilus receptor desmoglein-
2.  (A) Schematic of screen design. To screen for host genes responsible for type 1 pili-
dependent binding to this cell line, we transduced the Brie library of mouse guide RNAs into 
IMCD-3 cells bearing Cas9, providing 4× nominal coverage of each gene within the mouse 
genome. Cells were then bound (MOI 150) by UTI89 and sorted by fluorescent labeling, 
isolating cells unbound by bacteria. Genomic DNA was extracted and sequenced, identifying 
candidate genes that may be required for UPEC binding to IMCD-3 cells. (B) Volcano plot 
results from sorted and sequenced cells. Colored dots represent genes having an average log2 
fold change >0.5 and a –log10(p-value) >2.5. (C) After in vitro binding, desmoglein-2 (red) on 
IMCD-3 cells co-localized with UPEC (green); scale bar, 5 µm. Lower panel demonstrates co-




Figure 10. The FimH lectin domain directly binds DSG2 EC1-5 in a mannose-specific 
manner.  (A) Schematic of human DSG2, with five extracellular cadherin domains (EC1-5; 
blue) followed by a single transmembrane (TM) segment and the cytoplasmic (desmoglein) 
portion of the protein (gray). O-linked mannoses are represented by green dots, N-linked 
glycosylation sites with terminal mannose shown by yellow dots. (B) Normalized BLI signal 
(mean ± SD) of DSG2 ectodomains (immobilized at 1 µg/mL) binding to FimHLD or FimHQ133K 
(10 µM). Relative BLI signals were normalized to amount of captured WT DSG2 EC1-5. DSG2 
EC1-5 and DSG2 EC1-3 were purified from wild-type Expi293F cells, and DSG2 EC1-5 was 
also purified from Expi293F GnTI- cells (which lack complex N-glycans and instead exhibit 
uniform GlcNAc2Man5 glycosylation). *p=0.036 (EC1-5 WT vs Q133K), **p=0.008 (EC1-5 
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WT vs GnTI-), *p=0.015 (EC1-5 vs EC1-3). n= 3-5 independent experiments per group.
 
Figure 11. Purification of 6×His-tagged DSG2 EC1-5 from Expi293F cells.   (A) Coomassie 
blue-stained gel of FimHLD and FimHQ133K. (B) Coomassie blue-stained gel after metal-affinity 
purification of DSG2 EC1-5 and EC1-3 from cell supernatant. DSG2 EC1-5 was expressed in 
both WT Expi293F cells as well as in Expi293F GnTI- cells (lacking complex glycans). In right 
panel, due to its immunoglobulin folds, addition of the reducing agent DTT alters the apparent 




Figure 12. Biolayer interferometry tracings for binding of FimHLD to immobilized DSG2 
EC1-5. Biolayer interferometry (BLI) tracings for binding of FimHLD to immobilized DSG2 
EC1-5 expressed from WT Expi293F cells (left panel) or Expi293F GnTI- cells (right panel). A 
1:1 binding model (red lines) was used to fit experimental curves (black lines). Representative 
curves shown from 5 independent BLI runs per condition; affinity values represent the mean ± 
SD of two independent experiments.  
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Figure 13. Dsg2 knock-down cells exhibit a UPEC binding defect. (A) qPCR of desmoglein-2 
normalized to GAPDH in IMCD-3 Dsg2 knock-down clones C4 and F11 (C4/WT *p= 0.0458, 
F11/WT *p= 0.0449). n=3 independent samples per group, error bars represent standard error of 
the mean. (B) Quantitative immunoblot for Dsg2 in clones C4 and F11, normalized to β-actin 
(median C4/WT ratio 4.3%, * p=0.0022; median F11/WT ratio 4.7%, **p=0.0087). Inset shows 
representative blot. n=6 independent samples per group. (C, D) Binding of UTI89 to IMCD-3 
cells or to clones C4 and F11 (MOI 150) was quantified by flow cytometry after gating on single 
cells. (C) Histogram of FITC shift (anti-E. coli) in infected IMCD-3 cells. Medium alone (green) 
or infection with ∆fimH reflects no shift (orange); clones C4 and F11 (light and dark pink 
respectively) exhibited significantly decreased UPEC binding compared to WT IMCD-3 cells 
(navy blue). (D) Wild-type IMCD-3 cells infected with UTI89 displayed significantly higher 
median fluorescence intensity (MFI) than clones C4 and F11 (C4/WT *p= 0.0235; F11/WT 
**p=0.0032). n=15 samples per group over 5 independent experiments.  
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Figure 14. Mannoside treatment attenuates bladder and kidney infection.  (A) Schematic of 
mannoside treatment experiments. Male C3H/HeN mice were infected with UTI89; after 5 d, 
mice were administered mannoside 29R (8 mg/kg/dose IP) or vehicle (mock treatment) every 8 h 
for either 24 or 48 h. (B) Intratubular colonies of UPEC (teal) were observed 5 dpi in male 
C3H/HeN mice within desmoglein-2 positive (Dsg2+, red) collecting ducts (aquaporin-2 
[AQP2]+, green). DAPI, blue; scale bar, 10 µm. Mannoside treatment for 24 h (C) significantly 
reduced bacterial loads in the bladder (*p= 0.0255) and kidneys (*p=0.0434) (n=8-10 mice per 
group over 2 independent experiments), while an even more significant effect was seen with 48 h 






Table 2. Strains used in this study. 
 
  
Strain Description Reference 
UTI89 Prototypic UPEC isolate used for mouse 
infections and in vitro binding 
(16)  
UTI89 ∆fimH Type 1 pilus adhesin mutant in UTI89 (16)  
CFT073  Pyelonephritis/urosepsis isolate (89) 
CFT073 ∆fimH  Type 1 pilus adhesin mutant in CFT073 (89)  
UTI89 FimHWT Kan-resistant comparator for FimHA27V/ V163A (8) 
UTI89 FimHA27V/ V163A Functional variant of the FimH adhesin (8) 
UTI89 FimAWT   Spc-resistant comparator for FimAA22R (54) 
UTI89 FimAA22R Functional variant of the FimA pilus rod (54) 
UTI89∆yqi  Yqi operon knockout for mouse studies (90)  
UTI89∆sfaA-H Sfa operon knockout for mouse studies (90)  
UTI89∆yad Yad operon knockout for mouse studies (90)  
UTI89∆yfc Yfc operon knockout for mouse studies (90)  
UTI89∆yeh Yeh operon knockout for mouse studies (90)  
UTI89∆F17-like F17-like operon knockout for mouse studies (90)  
UTI89∆auf Auf operon knockout for mouse studies (90)  
UTI89∆papC Pap pilus usher knockout for mouse studies (83, 90)  
UTI89∆yagW Mat pilus adhesin knockout for mouse studies (83)  
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Table 3. Frameshift mutations within Dsg2 in IMCD-3 clones C4 and F11 (two allelic variants 
present in each clone are shown). 
C4 (1 bp deletion)  AGCCCTTGGAACTACGCATCAAA–TTCTGGACATCAATGACAACGAGCCA 
C4 (1-bp insertion)  AGCCCTTGGAACTACGCATCAAAGTTTCTGGACATCAATGACAACGAGCCA 
F11 (2-bp deletion) AGCCCTTGGAACTACGCATCAA– –TTCTGGACATCAATGACAACGAGCCA 





Table 4.  Probes and primers for qPCR. 
Gene  Assay  RefSeq Exon  Probe and Primers (P1/P2) 
Dsg2 Mm.PT.5
8.8263998 
NM_007883 6-7 5’-/56-FAM/TAGCTGCTG/ZEN/TGTTCCTCTCTGTCCA/3IABkFQ/-3’ 
P1:  5’-GAGCCTGCAAATAGTCATATGTTC-3’ 




NM_007393 5-6 5’-/56-FAM/CTGGCCTCA/ZEN/CTGTCCACCTTCC/3IABkFQ/-3’ 
P1:  5’-GATTACTGCTCTGGCTCCTAG-3’ 
P2:  5’-GACTCATCGTACTCTGCTTG-3’ 
Gapdh Mm.PT.3
9a.1 
NM_008084 2-3 5’-/56-FAM/TGCAAATGG/ZEN/CAGCCCTGGTG/3IABkFQ/-3’ 
P1:  5’-AATGGTGAAGGTCGGTGTG-3’ 







Table 5. CRISPR screen statistics for candidate genes those having an average log fold change 
>0.5 and a false discovery rate >2.5. Full data set of CRISPR screen analyzed ranks and statistics 
is available upon request. 




Xbp1 3.848596582 6.093119218 
Il6 3.141088217 5.256752426 
Ifnb1 2.695774915 5.509088383 
Tnf 1.740927366 2.813097061 
Dad1 1.005889469 2.827465023 
Cul4b 0.968090482 2.58455745 
Sars 0.864645208 2.945073915 
Dsg2 0.842438037 2.728006373 
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Chapter 5. Concluding Remarks and Future Directions 
 
Introduction 
Despite the importance of urinary tract infections (UTIs) in human health globally, we 
still lack a full understanding of the host and pathogenic factors involved in pyelonephritis. 
Previous technical barriers within the UTI field meant that preclinical studies historically have 
focused largely on the female murine bladder (1-4), which has indeed been fruitful. However, 
leveraging the development of new in vivo and in vitro models, the current body of work 
delineates the dynamics of kidney colonization by uropathogenic Escherichia coli (UPEC; the 
chief etiological agent of UTIs). We identified new host-pathogen interactions suitable for 
targeting by novel, non-antibiotic therapeutics, including androgen receptor antagonists as well 
as inhibitors targeting the interaction of the type 1 pilus adhesin FimH with host receptors. 
Collectively, this body of work provides fundamental understanding of key host-pathogen 
molecular interactions during pyelonephritis that will spawn and shape future biological and 
biomedical studies and lead to translatable interventions. 
 
Androgens play a key role in the development of severe pyelonephritis. 
We sought a mechanistic understanding of the role of androgens in the development and 
severity of pyelonephritis. While UTIs are typically considered a disease of women, UTIs in 
males are neither non-existent nor benign. Thus, to delineate the role of sex and sex hormones in 
the pathogenesis of UTI, we employed new mouse models of UTI in which males develop severe 
pyelonephritis in comparison to females. We described that exposure of female mice to 
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androgens enabled development of severe pyelonephritis, mimicking increased UTI risk in 
women with polycystic ovary syndrome (PCOS), a common hyperandrogenic state (5-7). 
Treatment of androgenized female mice with FDA-approved androgen receptor antagonists 
reversed this phenotype. We also demonstrated the presence of biofilm-like bacterial 
communities, termed kidney bacterial communities (KBCs), as a key pathogenic stage in 
pyelonephritis. This work implies that androgen modulation may represent a new therapeutic or 
preventive strategy for male UTI, in women with recurrent UTI (rUTI) and PCOS (8), and 
possibly in rUTI patients without clinical PCOS but with testosterone levels above the mean. 
Going forward, the cellular and molecular mechanisms by which androgen exposure modulates 
UTI must be identified, and other host factors that promote severe UTI outcomes should be 
investigated. 
 
Identify additional host factors involved in UPEC-induced pyelonephritis 
As we have determined that androgens in both male and female mice impart 
susceptibility to pyelonephritis (8, 9), we now desire to understand what androgen-responsive 
elements are activated, especially at the host-pathogen interface, to promote severe 
pyelonephritis? Specifically, it is critical to understand what cell types are involved. For 
example, it is possible that androgens act specifically on the non-hematopoietic compartment 
within the bladder and/or kidneys, upregulating receptors or otherwise making the androgenized 
epithelium more conducive to bacterial attachment or replication. Another possibility is that 
androgens shape the immune response to UPEC ascension in a way that hampers bacterial 
clearance and enables severe pyelonephritis. The androgen receptor (AR) is expressed widely in 
many cell types in male and female mammals, including leukocytes and most if not all cell types 
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in the kidney (10, 11). Of note, we have also demonstrated high expression of the AR within 
neutrophil-dominated renal abscesses (8). Thus, it is most likely that fundamental sex differences 
impact the host-pathogen interaction and cellular responses in pyelonephritis, thereby 
influencing pathogenicity, resolution, and subsequent renal scarring. 
As immune cells have been shown in other experimental systems to act differently in 
androgenized versus estrogenized hosts, a critical next step is understanding the influences of sex 
on susceptibility to pyelonephritis. As demonstrated in preclinical models with female C3H 
mice, an overzealous immune response early in infection leads to chronic cystitis and worsens 
infection outcome (12, 13). During human infection, bacterial infection of the renal parenchyma 
elicits marked tubulointerstitial inflammation (14-18). This inflammatory response is similarly 
reflected in our models, with established abscesses composed primarily of neutrophils destroying 
the surrounding renal parenchyma (8, 9, 19). Work in our lab and others has begun to delineate 
an altered immune response to UPEC in the presence of androgens (20-23). Specifically, our lab 
has demonstrated that while androgenized mice with UTI exhibit high levels of myeloid cell 
recruitment, UPEC are unable to be cleared from androgenized kidney. Androgen exposure 
increased the expression of activin A (a driver of renal scarring) in myeloid cells, helping to 
perpetuate scar formation; in part, this was attributable to prolonged polarization of macrophages 
toward a pro-fibrotic M2a phenotype (20). This work begins to link androgen influences on the 
innate immune response with increased susceptibility to severe pyelonephritis (8, 19, 20). 
Continued mechanistic studies will provide further understanding of hormonal effects during 
upper-tract UTI and illuminate ways to mitigate sequelae of severe pyelonephritis. 
Further, androgens also influence the expression of other, non-immune genes that could 
act in the development of upper-tract UTI. For example, expression of desmoglein-2, identified 
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in this work to be a receptor for UPEC FimH within the kidney (Chapter 4), is predicted to be 
influenced by various hormones and receptors (24, 25); however, the influence of various sex 
hormones on Dsg2 expression differs across model systems and target organs (24-27). 
Additionally, we are beginning to understand that other androgen-responsive non-hematopoietic 
genes influence host outcomes. Indeed, the process of fibrosis, which is initiated during abscess 
formation, is responsive to the influence of androgens. The presence of testosterone was found to 
increase local production of TGFβ1 before the initiation of experimental UTI. This testosterone-
induced surge of TGFβ1 increased the presence of mesenchymal stem cells and activated 
myofibroblasts, priming the kidney for fibrosis and collagen deposition (21). In other non-
infectious renal injury models, including unilateral ureteral obstruction (UUO), androgens 
enhance the severity of injury and scarring (28, 29). Together, these data paint a complex picture 
of androgens acting on cells of both hematopoietic and non-hematopoietic origin, interacting to 
create the inflammatory environment and tissue damage we observe in UPEC-infected males and 
androgenized females. 
We are now poised to elucidate these pathways further. Recently emerged technologies 
now permit detailed interrogation of sex-specific host responses in the kidney to ascending 
infection with UPEC. Specifically, future collaborative studies led by the Hunstad lab will 
employ single-nucleus RNA sequencing, using techniques developed in the Humphreys lab (28-
30), on kidneys from UPEC-infected and uninfected male, female, and androgenized female 
C3H mice. These studies will help to define how both chromosomal and hormonal sex influence 
the transcriptional responses of epithelial cells and of resident and recruited leukocyte subsets 
during ascending UPEC infection of the kidney. The results will provide a much more detailed 
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picture of the cellular and molecular pathways that comprise the host response to UPEC infection 
of the mammalian kidney, in both host sexes. 
 
Ascending UTI imposes a modest bottleneck on genetic diversity of infecting 
UPEC. 
During infection of the female mouse urinary tract, UPEC undergo a restrictive 
population bottleneck – first through the development of clonal intracellular bacterial 
communities (IBCs) and second through an ascension bottleneck in the kidney (resulting in 
female mice resolving kidney infection) (31). However, in male mice that develop severe 
pyelonephritis, we found that ascending pyelonephritis imposes only modest narrowing of 
genetic diversity among infecting UPEC. Using a set of “barcoded” isogenic UPEC isolates (31) 
and confocal microscopy, we defined the spatial and temporal dynamics of UPEC populations 
during experimental ascending pyelonephritis in mice. These analyses demonstrated relative 
preservation of infecting clones from 1-7 days post arrival in the kidney. Further, we found that 
kidney bacterial communities (KBCs) were clonal, despite being located in the urinary 
(extracellular) space and thereby lacking the invasion requirement that defines clonal IBCs in the 
bladder. Thus, at least in the present model, each KBC arises from growth and expansion of a 
single bacterial clone that ascended the nephron to establish a given intratubular focus of 
infection. These data further indicate that while bulk ascension into the kidney does not impose 
an acute bottleneck upon the bacterial population, individual nephron ascension is a 




Interrogate pathogenic factors using signature-tagged mutagenesis 
In female mice, large-scale signature-tagged mutagenesis screens to identify novel UPEC 
virulence factors have been precluded by the marked bottleneck imposed during the bladder IBC 
cascade and by spontaneous resolution of kidney infection in females of most mouse 
backgrounds (31). However, as our male kidney model does not impose such a bottleneck 
(Chapter 3), we can take multiple complementary approaches in order to delineate bacterial 
factors mediating kidney infection – namely high-throughput transposon-based screening 
techniques such as insertion-site sequencing (INSeq), as well as hybrid capture-enhanced 
bacterial RNA sequencing (RNAseq). These studies, funded by a recently awarded R01, are 
commencing in collaboration with the Earl group at the Broad Institute. Additionally, we 
developed an in vitro model of pyelonephritis using inner medullary collecting duct (IMCD-3) 
cells that accurately recapitulated the requirement for type 1 pili in renal tubular adherence 
(Chapter 4). Therefore, both INSeq and RNAseq could also be employed within this in vitro 
system to specify other UPEC factors that might be required for infection in vivo. Our ability to 
use contemporary RNA and DNA sequencing methods in both these models will enable the 
identification of novel, host-sex-specific UPEC virulence factors important in colonization, 
persistence, and disease causation in the kidney. 
Of particular interest, the UPEC adhesin profile and toxin profile during pyelonephritis 
remain to be further delineated. Unlike during female cystitis, in which type 1 pili are required 
immediately upon arrival in the bladder (32-35), our male model showed that type 1 pili were 
more critical at later time points (Chapter 4). This suggests a role for other bacterial products in 
bulk persistence within the renal pelvis, potentially including adherence in this initial kidney 
niche. However, our initial screen of chaperone-usher pathway pili (CUP pili) did not implicate 
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an alternative CUP pilus in UPEC pyelonephritis (recognizing that the P pilus receptor is 
minimally if at all expressed in the mouse kidney (36-38)). Additionally, among several 
canonical UPEC toxins we previously examined (α-hemolysin, cytotoxic necrotizing factor 1, 
OmpT), none were required for infection in this model (P. Olson, unpublished data; (39, 40)). 
Therefore, an unbiased screen to illuminate additional virulence factors during pyelonephritis 
will be essential to further understanding host-UPEC interactions in the kidney. 
 
UPEC adhesion to renal tubular epithelium is mediated by UPEC FimH 
binding to host desmoglein-2 (Dsg2).  
Type 1 pili of UPEC have long recognized to be critical for bacterial adhesion to the 
bladder (32, 34, 35, 41, 42). Using the male mouse model of UTI, we demonstrated an essential 
role for type 1 pili in colonizing the kidney during pyelonephritis. We showed that mannosides 
(novel small-molecule inhibitors of type 1 pili) can limit the severity of experimental 
pyelonephritis. Further, by performing a lentiviral CRISPR screen in cultured renal epithelial 
cells, we were able to identify host factors implicated in UPEC binding in the kidney. This 
screen identified a strong candidate type 1 pilus receptor on renal epithelium, namely 
desmoglein-2, a mannosylated, tight junctional protein (43, 44). Using both cellular assays and 
biochemical approaches, we confirmed that desmoglein-2 binds type 1 pili and that this 
interaction is critical for UPEC binding. Because we have now identified this key molecular 
interaction, mannosides and other therapeutics that target type 1 pilus binding can be further 
developed as non-antibiotic treatments for pyelonephritis. Future work will further interrogate 
the structure and in vivo interactions of desmoglein-2 in the kidney, as described below. 
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Interrogate the structural and in vivo interactions of type 1 pili and desmoglein-2 
We described the ability of the type 1 pilus adhesin, FimH, to bind purified human 
desmoglein-2 (DSG2) ectodomains (EC1-5). This interaction was mannose specific, as 
FimHQ133K, a non-mannose-binding mutant, was unable to bind DSG2. Further, the interaction 
was eliminated when the extracellular domain was truncated (DSG2∆EC4-5), suggesting that 
domains EC4 and/or EC5 mediate FimH binding. EC4 displays a unique, cadherin-specific form 
of mannosylation in which α-D-mannose (the canonical binding target of type 1 pili) is present as 
a novel O-linked glycosylation modification (43). As prior studies all have demonstrated FimH 
binding to N-linked glycans containing terminal mannose, it is intriguing to speculate that the O-
linked mannose on EC4 may represent the preferred binding target (41, 42, 45, 46). 
To interrogate the specific binding site of FimH, and specifically test the hypothesis that 
FimH interacts with O-linked mannose present on DSG2 EC4, multiple approaches are proposed. 
First, we can narrow to specific domains or perhaps peptide sequences that are responsible for 
UPEC binding by expressing DSG2 truncates or individual cadherin domains. Second, as FimH 
binding is mannose specific, point mutations targeting glycosylated residues within DSG2 EC4-5 
can eliminate specific glycans. This could help to specify the relative contributions of various 
mannose sites to FimH binding. As it is possible that binding of FimH can occur at multiple sites 
along DSG2, employing an array of these complementary methods (expressing specific domains, 
point mutations, blocking antibodies, treatment with specific glycosidases, etc.) will be 
maximally informative in determining the binding affinity and domain specificity of the DSG2-
FimH interaction. Of note, in the same lentiviral screen, we also sorted for cells that displayed 
higher binding of UPEC. This high binding population displayed many glycosyltransferases 
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(Figure 1), and thus could be further used to interrogate the effect of various sugars on UPEC 
binding.  
Additionally, future studies will interrogate in depth the structural basis of this 
interaction. Unlike at the bladder epithelial surface, where only a limited set of proteins 
(uroplakins) line the luminal surface and are thus available for binding, the renal tubular 
epithelium presumably expresses a wider variety of potentially mannosylated surface proteins.  
Our understanding of how regional amino acid and protein context impact FimH binding to 
mannose is currently minimal. What features would make one mannosylated protein residue a 
suitable (or high-affinity) receptor for FimH while others may bind poorly or not at all? It is 
unclear whether any mannosylated peptide – as long as it is sterically available to FimH – is 
capable of binding UPEC. While current dogma holds that FimH binds mannose specifically, no 
work has been done to understand if the protein scaffold plays any role in binding affinity or 
specificity. Therefore, an X-ray or cryoEM structure of the FimH-DSG2 complex may in fact 
expand our understanding of the range of biological interactions mediated by FimH.   
 
Determine the role of UPEC with Dsg2 with alternate in vivo niches 
While we know that UPEC co-localize with Dsg2 in vivo during kidney infection, we 
hope to study Dsg2 in conditional knockout mice to directly understand the how the expression 
of Dsg2 in different niches correlates to UPEC binding. We are currently generating mice with 
specific deletion of Dsg2 from renal tubular epithelia, which will allow us to further interrogate 
this mannosylated host protein as a type 1 pilus receptor in the kidney. As germline Dsg2 
knockout is embryonic lethal in mice (47), we are currently generating relevant conditional tools 
in the C3H background (C3H Dsg2fl/fl) to demonstrate the contribution of Dsg2 to the in vivo 
184 
pathogenesis of pyelonephritis. Crossing of Dsg2 floxed mice with various cell type-specific Cre 
mice (also being made in the C3H background) will enable us to interrogate where and when the 
FimH-Dsg2 interaction is most impactful. Specifically, we are creating C3H Ksp-Cre mice for 
both conditional and inducible knockout; here, the Cre recombinase is driven by the kidney-
specific cadherin (aka Cdh16) promoter, expressed in renal tubular epithelia (48, 49).  
Desmoglein-2 is expressed widely across mammalian epithelia (43, 44), thus raising the 
possibility that Dsg2 acts as a receptor for UPEC FimH in other niches relevant to UTI. 
Specifically, the exfoliated bladder epithelium is a potential site for UPEC-Dsg2 interactions. 
While uroplakin 1a is the canonical FimH receptor in the naïve bladder (41), the host response to 
initial bladder infection causes the uroplakin-coated superficial facet cells to be exfoliated (32, 
50-52). Underlying epithelial cells may express uroplakins at lower levels, but additional 
receptors likely also enable UPEC adherence to these newly exposed cells. In fact, Dsg2 is 
highly expressed on the bladder epithelial layers beneath the facet cells (Figure 2) (44). Further, 
UPEC have anecdotally been observed by scanning electron microscopy to line up along facet 
cell junctions (S.J. Hultgren, personal communication), where Dsg2 might be most highly 
expressed and available for interaction. These observations raise the distinct possibility that Dsg2 
plays a role in UPEC adherence within the bladder – either in the exfoliated bladder or as a 
secondary receptor during initial bladder colonization. 
 
Investigate the role of the innate immune response in UPEC kidney infection. 
It is clear that the innate immune response plays a critical role in pyelonephritis (53, 54). 
Renal abscesses are packed with infiltrating neutrophils, and C3H/HeJ mice (which lack a 
functional TLR4 response) subjected to experimental pyelonephritis succumb to urosepsis (8). 
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Further, in the CRISPR/Cas9 lentiviral screen for UPEC binding, there was an unpredicted but 
noticeable innate immune signature, including the genes Xbp1, Il6, and Ifnb, among others. The 
screen was conducted after 45 minutes of binding, selecting for cells that specifically displayed 
less binding of bacteria. Thus, future studies will interrogate how facets of the epithelial innate 
immune response to UPEC challenge may actually promote binding of the pathogen.   
One hypothesis is that epithelial cells, sensing the arriving pathogen, activate programs 
that function to reinforce tissue barriers, including intercellular junctions. In such a process, 
junctional proteins such as desmoglein-2, if expressed more highly, represent a means for 
increased bacterial binding to occur. Interestingly, 2 weeks post infection, we observed high 
expression of Dsg2 on many cell types within kidney abscesses (Figure 3). It is unclear whether 
activated neutrophils actively express Dsg2 or whether the destruction of renal parenchyma has 
exposed Dsg2 from other cellular sources (55). Immune cells do not canonically express Dsg2, 
and neutrophils show only low-level expression under normal conditions (44, 56). However, 
Dsg2 expression is predicted to be under the influence of immune signaling pathways (24, 25), 
raising the possibility that immune cells within the abscess do promote Dsg2 expression. An 
alternative hypothesis is that the major injury and cell death in renal parenchymal or epithelial 
cells exposes their Dsg2. Of note, in the intestinal tract, Dsg2 is cleaved intracellularly in 
response to injury or inflammation and subsequently released from cell surfaces (55). If this 
process were also occurring in renal abscesses, it might have the effect of reducing receptor 
availability on the epithelial surface, or to liberate a decoy molecule for FimH binding, as with 
Tamm-Horsfall protein in the urinary space (46, 57, 58). A third possibility is that immune 
activation results in the expression of alternative FimH receptors that were not specifically 
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detected in the screen. These all represent experimentally testable and nonexclusive hypotheses 
to be addressed in future work.   
 
Concluding remarks 
The present body of work defined essential host factors (androgens and desmoglein-2) 
and pathogen factors (type 1 pili and FimH) that are required for UPEC establishment of severe 
pyelonephritis. By employing new mouse models of UTI, we determined how androgenization of 
female mice leads to worsened kidney infection and demonstrated the presence of kidney 
bacterial communities as a key pathogenic stage in upper-tract UTI. We established that on a 
population level, high bacterial titers maintained overall genetic diversity, overshadowing the 
strict bottleneck that occurs in the bladder. However, at an individual nephron level, KBCs were 
formed by the clonal expansion of bacteria within a nephron unit. We then illuminated the 
dynamics and CUP pili adhesive profile of UPEC during renal abscess formation, revealing an 
essential role for type 1 pili in UPEC colonization of the renal epithelium during pyelonephritis. 
By generating a CRISPR-Cas9 lentivirus library in cultured renal epithelial cells, we screened for 
host factors implicated in UPEC binding in the kidney. This screen identified a receptor on renal 
epithelium for type 1 pili, desmoglein-2, and demonstrated that mannosides (novel small-
molecule inhibitors of type 1 pili) may be useful in treating pyelonephritis. In total, this work 
provides novel insights into the pathogenesis of pyelonephritis that could lead to more 
comprehensive, non-antibiotic therapeutic treatments. While the work advances our fundamental 
understanding of pyelonephritis, it also opens multiple new avenues of study in the UTI field to 





Figure 1. A lentiviral CRISPR screen identifies multiple glycosyltransferase enzymes 
involved in increasing UPEC binding.  To screen for host genes responsible for type 1 pili-
dependent binding to this cell line, we transduced the Brie library of mouse sgRNAs into IMCD-
3 cells bearing Cas9, providing 4× nominal coverage of each gene within the mouse genome. 
Cells were then bound (MOI 150) by UTI89 and sorted by fluorescent labeling, isolating cells 
highly bound by bacteria. Genomic DNA was extracted and sequenced, identifying candidate 
genes that may be required for UPEC binding to IMCD-3 cells. Volcano plot results from sorted 
and sequenced cells. Colored dots represent genes having an average log2 fold change >0.5 and a 




Figure 2. Desmoglein-2 expression on bladder epithelia.  Immunohistochemistry for DSG2 
expression in normal human bladder, showing strong expression in uroepithelium. Inset (lower 





Figure 3. Desmoglein 2 expression within renal abscess.  An image from the kidney of a 
C3H/HeN male mouse 2 wpi shows UPEC (green) within a KBC being infiltrated by immune 
cells (blue DAPI-stained nuclei). The immune cell infiltrate comprising the abscess can be seen 
highly expressing Dsg2 (red), suggesting a role of the innate immune system in local dsg2 
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